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A B S T R A C T
Background
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management
challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered as add-
on therapy to ICS.
Objectives
We compared the efficacy and safety profile of adding either daily LABA or LTRA in adults and children with asthma who remain
symptomatic on ICS.
Search methods
We searched the Cochrane Airways Group Specialised Register (up to and including March 2010). We consulted reference lists of all
included studies and contacted authors and pharmaceutical manufacturers for other published or unpublished studies.
Selection criteria
We included randomised controlled trials (RCTs) conducted in adults or children with recurrent asthma that was treated with ICS and
where a fixed dose of a long-acting beta2-agonist or leukotriene agent was added for a minimum of 28 days.
Data collection and analysis
Two authors independently assessed the risk of bias of included studies and extracted data. We sought unpublished data and further
details of study design, where necessary.
Main results
We included 17 RCTs (7032 participants), of which 16 recruited adults and adolescents (6850) and one recruited children aged 6 to
17 years (182). Participants demonstrated substantial reversibility to short-acting beta-agonist at baseline. The studies were at a low
risk of bias. The risk of exacerbations requiring systemic corticosteroids was lower with the combination of LABA and ICS compared
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with LTRA and ICS, from 11% to 9% (RR 0.83, 95% CI 0.71 to 0.97; six studies, 5571 adults). The number needed to treat (NNT)
with LABA compared to LTRA to prevent one exacerbation over 48 weeks was 38 (95% CI 22 to 244). The choice of LTRA did not
significantly affect the results. The effect appeared stronger in the trials using a single device to administer ICS and LABA compared to
those using two devices. In the absence of data from the paediatric trial and the clinical homogeneity of studies, we could not perform
subgroup analyses on age or asthma severity. The addition to ICS of LABA compared to LTRA was associated with a statistically greater
improvement from baseline in several of the secondary outcomes, including lung function, functional status measures and quality of
life. Serious adverse events were more common with LABA than LTRA, although the estimate was imprecise (RR 1.35, 95% CI 1.00
to 1.82), and the NNT to harm for one additional patient to suffer a serious adverse event on LABA over 48 weeks was 78 (95% CI 33
to infinity). The risk of withdrawal for any reason in adults was significantly lower with LABA and ICS compared to LTRA and ICS
(RR 0.84, 95% CI 0.74 to 0.96).
Authors’ conclusions
In adults with asthma that is inadequately controlled on low doses of inhaled steroids and showing significant reversibility with beta2-
agonists, LABA is superior to LTRA in reducing oral steroid treated exacerbations. Differences favouring LABA in lung function,
functional status and quality of life scores are generally modest. There is some evidence of increased risk of SAEs with LABA. The
findings support the use of a single inhaler for the delivery of LABA and inhaled corticosteroids. We are unable to draw conclusions
about which treatment is better as add-on therapy for children.
P L A I N L A N G U A G E S U M M A R Y
What are the effects of long-acting beta2-agonists compared with anti-leukotrienes when added to inhaled steroids?
People who continue to experience asthma symptoms despite regularly taking inhaled corticosteroids are a challenge for management.
It is not clear whether the addition of a long-acting beta2-agonist (LABA) such as formoterol or salmeterol would provide more benefit
in comparison with an oral anti-leukotriene agent (LTRA), for example zafirlukast or montelukast.
Seventeen trials (16 in adults and one in children) were included in this review and were of good quality. We found that the addition of
a LABA provides significantly greater protection against exacerbations requiring oral steroids when compared with a LTRA for adults.
Based on the results of our analyses, approximately 38 adults (with a range of between 22 and 244) would need to be treated with a
LABA rather than a LTRA for 48 weeks to prevent one experiencing an exacerbation needing a course of oral steroids. The trial on
children did not contribute data on the main outcome and therefore we could not draw any conclusions for children.
LABAs also led to a greater improvement in lung function, improvement in symptoms, use of rescue medication, quality of life and
symptoms compared to the use of LTRAs. The magnitude of the improvements was modest. Serious adverse events were more frequent
with LABA than with LTRAs although this result was imprecise. Based on our analyses, around 78 people would need to be treated for
48 weeks with a LABA rather than a LTRA for one of them to experience a serious adverse event. However, due to the lack of precision
around our result, the true number could be between 33 and infinity. There are currently insufficient data to draw any conclusions
about the effects of these drugs in children.
B A C K G R O U N D
Leukotrienes are inflammatory molecules and are one of sev-
eral substances released by mast cells during the immediate re-
sponse to an inhaled allergen. They are derived from arachidonic
acid, the precursor of prostaglandins (Wasserman 1988; Wenzel
1997). There are two families of leukotrienes. Leukotriene B4
acts primarily in conditions in which inflammation is dependent
on neutrophils, such as cystic fibrosis, inflammatory bowel dis-
ease, and psoriasis. The second group (C4, D4, E4), called cys-
teinyl-leukotrienes, bind to highly selective receptors to induce
eosinophil- and mast cell-induced bronchoconstriction and in-
flammation associated with asthma (Davis 1997). Drugs that can
interfere with the production (leukotriene synthesis inhibitors)
and activity (leukotriene receptor antagonists) of leukotrienes have
beendesigned. Leukotriene synthesis inhibitors (for example zileu-
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ton) inhibit the enzyme 5-lipoxygenase thus blocking the pro-
duction of many leukotrienes (for example B4, C4, D4, and E4)
(Georgitis 1999). Leukotriene (cysteinyl) receptor antagonists (for
example montelukast, zafirlukast, pranlukast) block leukotriene
D4 (LTD4) receptors (Georgitis 1999). Both types of leukotriene
modifiers are administered orally as tablets.
Two Cochrane reviews have concluded that leukotriene receptor
antagonists (LTRA) are mild anti-inflammatory agents when used
as monotherapy (Ducharme 2004b) and bring modest benefit
as add-on therapy to inhaled steroids (Ducharme 2004a). Long-
acting beta2 (β2)-agonists (LABA) have a similar mode of ac-
tion to that of short-acting β2-agonists. Some LABAs may have
a slightly slower onset of action than short-acting β2-agonists
(SABA, Lotvall 1996) but display prolonged activation of β2-re-
ceptors (Johnson 1995) in bronchial smooth muscle resulting in
prolonged duration of action, for up to 12 hours (Rees 1995).
LABA are recommended solely as add-on therapy to inhaled cor-
ticosteroids (ICS) in patients with moderate to severe asthma who
remain symptomatic despite anti-inflammatory therapy (BTS
2009; GINA; Lougheed 2010). A number of concerns have been
raised about the safety of LABA, predominantly when used with-
out concomitant ICS (Cates 2008a; Cates 2008b; Salpeter 2006;
Walters 2007). Due to evidence of increased risk of severe exacer-
bations and death, there has been a recent call for the withdrawal
of inhalation devices containing only LABA. The combination of
LABA with ICS has been carefully examined and is superior to
placebo when introduced as a second-line therapy in adults treated
with ICS (Ducharme 2010; Ernst 2006). In children already tak-
ing ICS and in steroid-naive patients, there remains some uncer-
tainty as to whether additive LABA confers any meaningful bene-
fit (Ni Chroinin 2009a; Ni Chroinin 2009b). Despite non-statis-
tically significant results for outcomes relating to serious adverse
events, the data do not prove conclusively that the risk of serious
adverse events is abolished by the presence of ICS (Cates 2009a;
Cates 2009b).
People with asthma who continue to experience symptoms with
ongoing airway obstruction despite taking regular ICS represent
a management challenge. Both leukotriene receptor antagonists
(LTRAs) and LABA agentsmay be considered as add-on therapy to
ICS (Adams 2007). There are several reasons to support the syner-
gistic effect of either combination at the cellular or pathophysiol-
ogy level. LABAs reduce airway hyper-responsiveness by means of
functional antagonism (Lipworth 2002) while corticosteroids in-
crease the expression of β2-adrenergic receptors (Baraniuk 1997),
which is a good combination for synergy. LTRAs inhibit the pro-
duction of cysteinyl leukotrienes, important pro-inflammatory
mediators in asthma that are unaffected by steroid treatment.
LTRAs are particularly effective in allergen-, exercise-, and as-
pirin-induced asthma (Krawiec 2002). Thus, both the addition
of LTRAs or LABA could potentiate the anti-inflammatory effect
of inhaled corticosteroids and lead to better asthma control. The
current review compares the relative benefits and safety profile of
adding either an LTRA or a LABA to the treatment of patients
with asthma who are inadequately controlled by ICS and updates
a previous Cochrane review (Ducharme 2006).
O B J E C T I V E S
To compare the safety and efficacy of adding LABA versus LTRA in
children and adults with asthma who remain symptomatic in spite
of regular treatment with ICS. We specifically wished to examine
the relative impact of the two agents on asthma exacerbations,
lung function, symptoms, quality of life, adverse health events,
and withdrawals.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCT) conducted in
adults or children in whom a long-acting β2−agonist (LABA) or
leukotriene receptor antagonist (LTRA) were added, as a fixed-
dose combination, to ICS.
Types of participants
Children or adults with recurrent or persistent asthma treated with
inhaled steroids (ICS) as the only asthma control medication prior
to study entry.
Types of interventions
Interventions included LABA (for example salmeterol or for-
moterol) or LTRA (for example montelukast, pranlukast, zafir-
lukast, or zileuton). Participants were required to be on a stable
dose of ICS throughout the treatment period. The intervention
must have been administered for a minimum of 28 days. Inhaled
short-acting β2-agonists and short courses of oral steroids were
permitted as rescue interventions.
Types of outcome measures
Primary outcomes
Number of patients with asthma exacerbations requiring a rescue
short course of systemic corticosteroids.
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Secondary outcomes
1. Other measures of severity of exacerbations, such as
hospital admissions.
2. Measures reflecting chronic asthma control such as
pulmonary function tests; symptom scores; days or nights
without symptoms, or both; quality of life; use of rescue fast-
acting β2-agonists; and patient satisfaction.
3. Measures of inflammation such as eosinophilia, serum
eosinophil cationic protein, and sputum eosinophils.
4. Adverse effects including rates of clinical and biochemical
adverse effects.
5. Withdrawal.
Search methods for identification of studies
Electronic searches
Trials were identified using the Cochrane Airways Group Spe-
cialisedRegister of trials (searched up toMarch 2010), which is de-
rived from systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library), MEDLINE, EMBASE, and CINAHL;
and handsearching of respiratory journals and meeting abstracts
(please see the Airways Group search methods for further details).
All records in the Specialised Register coded as ’asthma’ were
searched using the following terms:
(((beta* ANDagonist*) AND(long-actingOR“long acting”))OR
((beta* AND adrenergic*) AND (long-acting OR “long acting”))
OR (bronchodilat* AND (long-acting OR “long acting”)) OR
(salmeterol OR formoterol OR eformoterol OR advair OR sym-
bicort)) AND (((steroid* OR glucocorticoid* OR corticosteroid*)
AND inhal*) OR (budesonide OR beclomethasone OR flutica-
sone OR triamcinolone OR flunisolide)) AND (leucotrien* OR
leukotrien*ORanti-leukotrien*ORanti-leucotrien*OR*lukast).
An additional search ofCENTRALwas completed using the above
search strategy.
Searching other resources
We reviewed reference lists of all included studies and reviews
to identify potentially relevant citations. We asked authors of in-
cluded studies and pharmaceutical companies to identify other
published or unpublished studies. We searched abstract books of
the American Thoracic Society (ATS) and European Respiratory
Society (ERS) (1998 to 2005) by hand. For the 2006 and 2010
updates, we accessed a register of study results posted by pharma-
ceutical manufacturers (www.clinicalstudyresults.org). This web-
site lists study results from the manufacturers of LABAs (GSK,
AstraZeneca) and LTRAs (Merck, AstraZeneca).
Data collection and analysis
Selection of studies
Two of us screened the title, abstract or descriptors and excluded
all studies that were clearly not RCTs or that clearly did not fit
the inclusion criteria. Two of us reviewed the full-text documents
of the remaining trials, assessing for inclusion based on popula-
tion, intervention, study design, and outcome. We searched the
bibliographies of articles that we retrieved in full to identify any
additional studies.
Data extraction and management
Data for the trials were extracted by two authors and entered into
ReviewManager 5. Where necessary, expansions of graphic repro-
ductions and estimations from other data presented in the papers
were performed.
We contacted primary study authors to confirm methodology and
data extraction as well as to provide additional information and
clarification, if needed.
Assessment of risk of bias in included studies
We assessed the risk of bias for each study in terms of allocation
generation and concealment, blinding, handling of withdrawals,
and selective reporting bias (see Chapter 8 of the Cochrane
Handbook) (Higgins 2008). This replaced the previous method-
ology for assessing study quality (see Differences between protocol
and review).
We assessed the risk of bias of each study for the following six
items.
1. Allocation generation.
2. Allocation concealment.
3. Blinding.
4. Incomplete data.
5. Selective reporting.
6. Other potential sources of bias.
Our judgments of high, low, and unclear risk of bias were corrob-
orated by quotations from trial reports, correspondence, or sum-
marized information from the relevant sections of the individual
study reports.
Assessment of heterogeneity
We measured heterogeneity of effect sizes between studies with
the I2 statistic (Higgins 2003). If heterogeneity was suggested by
I2 > 25%, a random-effects model was applied to the summary
estimates and was reported in the results.
Subgroup analyses were planned to explore possible effect modi-
fications associated with a priori identified variables or to explore
the cause of heterogeneity of study results, if any, for the main
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outcome. Differences in the magnitude of effect attributable to
these subgroups were examined with the residual Chi2 test from
the odds ratios (Deeks 2001).
Data synthesis
All included trials were combined using Review Manager 5. For
dichotomous variables, we combined data as a pooled fixed-effect
model risk ratio (RR) with 95% confidence interval (95% CI).
For continuous outcomes we combined data as a pooled fixed-
effect model mean difference (MD) or standard mean difference
(SMD) with 95% CI. We calculated the number needed to treat
(NNT) for the primary outcome using Visual Rx, a web-based
programme available via www.nntonline.net (Cates 2002).
Odds ratios were used for NNT as the results are not affected by
the selection of the reference treatment (LABA or LTRA). In view
of the different duration of the trials, the pooled odds ratio was
applied to the average exacerbation rate in the trials to give NNTs
for 12 and 48 weeks of treatment.
Subgroup analysis and investigation of heterogeneity
1. Number of inhaler devices used to deliver LABA and ICS
therapy (added after publication of the protocol, seeDifferences
between protocol and review)
2. Dose and type of long-acting β2-agonist (salmeterol,
formoterol)
3. Dose and type of anti-leukotriene (montelukast,
pranlukast, zafirlukast, zileuton)
4. Dose and type of ICS (in beclomethasone-equivalents)
5. Children versus adults
6. Baseline severity of airway obstruction based on the per
cent predicted forced expiratory volume in one second (FEV1),
or peak expiratory flow (PEF): severe < 60%, moderate 61% to <
80%, mild ≥ 80% (GINA 2009)
Sensitivity analysis
For the primary outcome, we planned to perform the following
sensitivity analyses to investigate the potential effect of study du-
ration (≤ 12 weeks, > 12 weeks), publication bias, risk of bias,
and funding source (trials funded by producers of LABA, studies
funded by producers of LTRA, independently-funded studies) on
the study results. Funnel plots were used to test for the presence
of publication and other biases for trials contributing data to the
main outcomes (Egger 1997).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
See Table 1 for details of the search history which formed the basis
of the previous version of the review (all years to January 2006).
Three studies from searches conducted between January 2006 and
March 2010 met the eligibility criteria of the review (ELEVATE;
Lemanske 2010; Pavord 2007). We re-assessed the eligibility of
one previously included study and excluded it due to pre-trial
exposure to combination therapy (Stelmach 2008). The addition
of three new studies and the exclusion of Stelmach 2008 gave a
total of 17 included studies reported in 45 publications (see Figure
1).
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Figure 1. Literature flow diagram for studies included in 2010 update of the Cochrane review.
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Included studies
The studies were reported as 13 full-text journal publications
(Bjermer 2003; Ceylan 2004; ELEVATE; Fish 2001; Green 2006;
Grosclaude 2003; Ilowite 2004; Lemanske 2010; Nelson 2000;
Nelson 2001; Pavord 2007; Ringdal 2003; Storms 2004), two un-
published full-text company reports (SAM40030; SD-004-0216)
and two conference abstracts (Hendeles 2004; Nsouli 2001). The
conference abstracts did not provide data in sufficient detail to
contribute to the meta-analyses, and we have not been able to
obtain data from the investigators through correspondence. We
describe below the characteristics of the 15 included studies which
contributed data to the review.
Design
All but one trial employed a parallel-group design. Lemanske 2010
was a three-arm cross-over trial conducted in children. The authors
declined our request for additional data to enable inclusion of any
data from this study in the review.
Participants
Fourteen trials focused on adults, with mean ages ranging from
35 to 44 years, with similar gender representation and mean
asthma duration ranging from 10 to 26 years. One study re-
cruited children aged between six and 17 years (Lemanske 2010).
Most trials (Bjermer 2003; Ceylan 2004; Fish 2001; Grosclaude
2003; Ilowite 2004; Nelson 2000; Ringdal 2003; Storms 2004)
allowed the inclusion of adolescents aged ≥15 years (or ≥ 12
years for SD-004-0216 and Nelson 2001) although the number
of teenagers randomised, if any, was not reported. All but one
trial clearly specified that participants could not be steroid naive at
enrolment; the remaining study, which failed to specify whether
this was a specific criterion for eligibility (Nelson 2001), was still
included.
Participants were symptomatic at enrolment despite inhaled
steroids at doses of 200 to 1000 µg/day of chlorofluorocar-
bon (CFC)-propelled beclomethasone or equivalent (CFC-BDP),
when ICS doses were reported. Severity of asthma as measured by
degree of airway obstruction was available for one study. Based
on categorisations outlined by GINA of: mild obstruction, FEV1
80% predicted or higher;moderate, FEV1 60% to 80% predicted;
severe, less than 60% predicted, the mean FEV1 indicated that
participants had mild airway obstruction in two trials (Lemanske
2010; Storms 2004) and moderate airway obstruction in 11 tri-
als (Bjermer 2003; Ceylan 2004; Fish 2001; Green 2006; Ilowite
2004; Nelson 2000; Nelson 2001; Pavord 2007; Ringdal 2003;
SAM40030; SD-004-0216). We were not able to ascertain base-
line FEV1 for two studies (ELEVATE; Grosclaude 2003).
Allergy status was reported in two studies (Bjermer 2003;
Lemanske 2010) where 65% and 77% respectively of participants
were affected at baseline. Three studies (Bjermer 2003; Ceylan
2004; Grosclaude 2003) reported that 60%, 65%, and 51% re-
spectively of participants suffered from allergic rhinitis.
Withdrawal rates varied from 8% to 17% in the LTRA group and
5% to 27% in the LABA group.
Intervention
During the intervention period, all participants remained on a
stable dose of inhaled corticosteroids (ICS). For the purposes of
this review, we considered low ICS doses to be 400 µg/day or
less (CFC-BDP equivalent), moderate doses to be 400 to 800 µg/
day (CFC-BDP equivalent) and high doses as 800 µg/day (CFC-
BDP equivalent) or higher. Based on these categorisations, most
of the studies assessed the addition of LABAs or LTRAs to low and
moderate doses of ICS (see Table 2). Two trials failed to report the
dose of background ICS (ELEVATE; Nelson 2001).
The LTRAs and doses administered were: zafirlukast 20 mg
twice daily (Nelson 2001; SD-004-0216) and montelukast 10
mg once daily (Bjermer 2003; Ceylan 2004; Fish 2001; Green
2006; Grosclaude 2003; Ilowite 2004; Lemanske 2010; Nelson
2000; Pavord 2007; Ringdal 2003; SAM40030; Storms 2004).
ELEVATEwas a pragmatic study in which study participants were
allocated to either montelukast or zafirlukast.
The LABAs used were: salmeterol 50 µg twice daily in seven tri-
als (Bjermer 2003; Fish 2001; Grosclaude 2003; Ilowite 2004;
Lemanske 2010; Nelson 2000; Nelson 2001; Pavord 2007;
Ringdal 2003; SAM40030; Storms 2004) and formoterol 12 µg
twice daily in three trials (Ceylan 2004; Green 2006; SD-004-
0216). ELEVATE was a pragmatic study in which study partici-
pants were allocated to either formoterol or salmeterol.
In seven studies, the combination therapy (Seretide®, Advair®
or Symbicort®) was administered in a single device (Green 2006;
Grosclaude 2003; Lemanske 2010; Nelson 2000; Pavord 2007;
Ringdal 2003; SAM40030) and by separate inhaler devices in
seven studies (Bjermer 2003; Ceylan 2004; Fish 2001; Ilowite
2004;Nelson2001; SD-004-0216; Storms 2004).Wewere unable
to determine the number of inhalers used to deliver therapy in
ELEVATE.
The intervention period varied between four weeks (Nelson 2001;
Storms 2004), six weeks (Green 2006), eight weeks (Ceylan
2004; SD-004-0216), 12 weeks (Fish 2001; Grosclaude 2003;
Pavord 2007; Nelson 2000; Ringdal 2003; SAM40030), 16 weeks
(Lemanske 2010), 48 weeks (Bjermer 2003; Ilowite 2004), and
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two years (ELEVATE).
Outcomes
The primary outcome (the number of participants with exacerba-
tions requiring rescue systemic corticosteroids) was available for
six trials contributing to the main outcome (Bjermer 2003; Fish
2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal 2003),
representing 77% of the total number of participants (81% of
adults and 0% children) randomised to trials included in this re-
view. For four trials we could not satisfactorily identify the require-
ments for oral steroids as binary data (ELEVATE; Green 2006;
Grosclaude 2003; Lemanske 2010). None of the studies identified
since the first version of the review contributed additional data to
our primary outcome.
Other measures of asthma control (for example pulmonary func-
tion tests, symptoms, use of rescue β2-agonist, quality of life),
withdrawals and adverse effects were reported by several included
studies.
Excluded studies
Of the 69 citations retrieved since the 2006 version of the review,
we excluded 66 records because:
1. the study was a duplicate (i.e. identical citation of a trial
report or a subsequent report of a trial), N = 29;
2. the study was not randomised, N = 2;
3. the study was ongoing, N = 5;
4. the administration of either LTRA or LABA was not
standardised across treatment groups, N = 3;
5. there was no consistent co-treatment with inhaled
glucocorticoids, N = 8;
6. one of the tested interventions was not daily LTRA as add-
on to inhaled glucocorticoids, N = 9;
7. one of the tested interventions was not daily LABA as add-
on to inhaled glucocorticoids, N = 2;
8. the tested interventions were administered for less than four
weeks, N = 1;
9. the study used prohibited co-intervention, N = 3;
10. the study did not recruit participants at the step 2* level, i.e.
the study recruited steroid-naive participants or participants on
combination therapy, N = 3
* Step 1, 2, and 3 refer to levels of asthma treatment (BTS 2003).
Risk of bias in included studies
An overview of our judgments for the risk of bias of each study is
provided in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
9Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Randomisation was clearly described and appropriate in all trials
with the exception of three trials that contributed data to the
review (Ceylan 2004; Grosclaude 2003; SD-004-0216) and the
two abstracts not contributing data in sufficient detail to be meta-
analysed (Hendeles 2004; Nsouli 2001). All the data included in
the primary outcome were drawn from six studies with robust
random sequence generation and allocation concealment.
Blinding
Twelve trials reported double blinding with identical ’dummy’
treatments, while three trials (Ceylan 2004; Grosclaude 2003;
Nsouli 2001) had an open-label design. One trial failed to clearly
report the means of blinding (Hendeles 2004).
The methodology was confirmed by the authors of all trials
contributing data with the exception of three (Ceylan 2004;
Grosclaude 2003; Storms 2004). No confirmation was obtained
for two studies reported as abstracts (Hendeles 2004; Nsouli
2001).
The six trials contributing data to the primary outcome were dou-
ble-blind, double-dummy studies.
Incomplete outcome data
Withdrawal rates were described in all but one study (Nsouli
2001). Withdrawals were not reported in three trials by treatment
group (Ceylan 2004; ELEVATE; Lemanske 2010).
The analyses within the studies were frequently described as being
by intention to treat. However, further information as to how
missing data were handled in the trials was limited. For one trial,
data were from patients who completed the study (Nelson 2001).
Selective reporting
The amount of data for the review primary outcome was high
when considered as the proportion of the total participants ran-
domised (77%).Wewere unable to use data fromother studies due
to their broader definition of exacerbations or inadequate report-
ing of outcome data (ELEVATE; Green 2006; Grosclaude 2003;
Lemanske 2010). In one study, exacerbations were not measured
(Pavord 2007) and in another there were no occurrences (Storms
2004). From the remaining five studies, we could not ascertain
whether exacerbations were measured.
Effects of interventions
Primary outcome: exacerbations requiring oral (systemic)
corticosteroids
Six trials with 5571 adults (no children) contributed data to the
primary outcome (Bjermer 2003; Fish 2001; Ilowite 2004;Nelson
2000; Nelson 2001; Ringdal 2003). The risk of having an exac-
erbation requiring systemic corticosteroids was statistically signif-
icantly lower with the use of LABA and ICS compared to LTRA
and ICS (RR 0.83, 95% CI 0.71 to 0.97) (Figure 3). The addition
of LABA lowered the risk of an exacerbation from 11% to 9%, a
2% (95% CI 0 to 3%) risk difference in exacerbations requiring
systemic steroids over the use of LTRA. The number of patients
who needed to be treated (NNT) with the combination of LABA
and ICS instead of LTRA and ICS to prevent one exacerbation
over 48 weeks was 38 (95% CI; 22 to 244), as shown in a Cates
plot in Figure 4. For the shorter 12-week trials the NNT was 106
(95% CI 63 to 676).
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Figure 3. Forest plot of comparison: 1 Leukotriene receptor antagonists + ICS versus Long-acting ß2-
agonists + ICS, outcome: 1.1 Participants with one or more exacerbations requiring systemic corticosteroids.
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Figure 4. In the LRTA group 16 out of 100 had an exacerbation requiring oral corticosteroids over 48 weeks,
compared to 14 (95% CI 12 to 16) for the LABA group. The NNT with LABA to prevent one patient having an
exacerbation over 48 weeks is 38 (95% CI 22 to 244).
The results were homogeneous despite the different LABAs and
LTRAs used (I2 = 6%). Although the funnel plot intercept sug-
gested no evidence of publication bias (-0.01, 95% CI -4.23 to
2.10) visual inspection of the funnel plot precludes firm reassur-
ance (Figure 5). The number of unpublished studies with null re-
sults needed to overturn the current findings was nine.
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Figure 5. Funnel plot of comparison: 1 Leukotriene receptor antagonists + ICS versus Long-acting ß2-
agonists + ICS, outcome: 1.1 Participants with one or more exacerbations requiring systemic corticosteroids.
Although there was no heterogeneity between trials, we had
planned a priori to perform subgroup analyses on the following
variables, to explore their possible influence on the magnitude of
effect (effect modification). The subgroup comparison between
single and combined inhalers was added after publication of the
initial protocol as a result of work subsequently published on this
topic (Nelson 2003).
1. Number of inhaler devices used to deliver LABA and ICS
Of the six studies contributing outcome data to the primary out-
come, there were two studies (Nelson 2000; Ringdal 2003) where
LABA and ICS were delivered in one inhaler device and four stud-
ies (Bjermer 2003; Fish 2001; Ilowite 2004; Nelson 2001) where
separate inhalers were used. Use of a single inhaler provided sig-
nificantly greater protection against exacerbations than use of sep-
arate inhalers (Analysis 2.1). We calculated the ratio of risk ratios
(RRR) as 0.55 (95% CI 0.31 to 0.95; P = 0.04) (Altman 2003). In
other words, the protective effect seen with single inhaler devices
that combined ICS and LABA on exacerbations requiring rescue
oral corticosteroids was almost twice that of the separate inhaler
devices as compared to ICA and LTRA. However, this indirect
comparison is confounded by other differences between trials, in-
cluding trial duration and ICS dose.
2.Dose and type of LABA
All included studies contributing data towards the meta-analysis
used salmeterol as the LABA, preventing assessment of the within-
class effect of LABA.
3. Dose and type of LTRA
The type of LTRA used in the included trials did not appear to
make a difference on the primary outcome. The RR of exacer-
bations when LABA + ICS was compared to montelukast + ICS
and zafirlukast + ICS was 0.83 (95% CI 0.71 to 0.97) and 0.86
(95% CI 0.29 to 2.52) respectively, with no statistical difference
between the two subgroups (Analysis 1.1).
4. Dose and type of inhaled corticosteroids (in
beclomethasone-equivalent doses)
All six studies included in the primary outcome were reported to
have used similar doses of inhaled glucocorticoids, ranging from
200 to 282 µg/day of HFA-BDP equivalents. There were no sub-
group differences between those with low, moderate, mixed, or
unclear ICS dose (Analysis 2.2). Fluticasone was used in four trials
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(Bjermer 2003; Ilowite 2004; Nelson 2000; Ringdal 2003). One
trial used a variety of ICSs as the authors kept patients on their
usual ICS (Fish 2001); and we were unable to obtain details on
the ICS used in Nelson 2001.
5. Children versus adults
Since the paediatric trial did not contribute any outcome data
to this review, the effect on children versus adults could not be
examined.
6. Baseline severity of airway obstruction
As the studies pertained to patients with moderate airway ob-
struction who were relatively homogeneous in the average base-
line FEV1 (all within 66% to 76% of predicted value), subgroup
analyses of baseline severity could not be performed.
7. Duration of trials
The two trials of 48 week duration showed a smaller difference
in treatment effect ((RR 0.88; 95% CI 0.74 to 1.04) than the
other trials of 12 week duration or less (RR 0.65; 95% CI 0.45
to 0.96), although the confidence intervals were overlapping and
the difference between the longer and shorter trials was not sta-
tistically significant (Chi2 = 1.93, df = 1, P = 0.16, Analysis 2.3).
However, the difference in trial durations could be a confounding
factor when considering the subgroup difference between single
and separate inhalers.
The studies contributing to the primary outcome were at a low
risk of bias, funded by manufacturers of the study drugs, and were
all published. The pooled result was not sensitive to bias from
any of the sources we assessed and we could not ascertain whether
funding source or publication status affected the estimated effect.
Secondary outcomes
Morning peak expiratory flow (PEF) (L/min change from
baseline)
Eleven studies in 5723 adults contributed data to the morning
PEF results. There was a greater improvement in morning PEF
with LABA compared with LTRA (15.36 L/min, 95% CI 11.35
to 19.37) (Analysis 1.2).
Evening PEF (L/min change from baseline)
Ten studies in 4012 adults contributed data to the meta-analysis
of evening PEF. There was a significantly greater improvement
in evening PEF with LABA compared with LTRA (12.64 L/min,
95% CI 10.11 to 15.17) (Analysis 1.3).
Forced expiratory volume in one second (FEV1) (L/sec
change from baseline)
Ten studies in 4538 adults contributed data to changes in FEV1.
There was a greater improvement in FEV1 with LABA compared
with LTRA (0.08 L/sec, 95% CI 0.06 to 0.10) (Analysis 1.4).
FEV1 (L/sec, % change from baseline)
As only one adult trial contributed date to this outcome (Ceylan
2004), we were unable to pool data (Analysis 1.5).
FEV1 (% predicted)
As one small adult study contributed data to this outcome, we
were unable to pool data (Analysis 1.6).
FEV1 (% fall post-exercise)
One small adult study contributed data to this outcome (Analysis
1.7).
Rescue-free days (% change from baseline)
Five studies conducted in 2612 adults contributed data to change
in per cent of rescue medication-free days. LABA + ICS showed
an increase in the percentage of days with no rescue medication
use compared to LTRAs + ICS (MD 9.18, 95% CI 5.39 to 12.98)
(Analysis 1.8).
Rescue medication use (puffs/day)
Seven studies in 4055 adults contributed data on rescue medica-
tion. The combined overall estimate showed a significant decrease
in the use of rescue medication with LABA + ICS (MD -0.49
puffs/day, 95% CI -0.75 to -0.24) (Analysis 1.9).
Change in global asthma quality of life score (higher score is
better) - change from baseline
Three studies in 2893 adults reported asthma-specific quality of
life using the Juniper’s 24-point scale: Bjermer 2003; Ilowite 2004
using montelukast, and Nelson 2001 using zafirlukast. The overall
estimate showed an improvement in global asthma quality of life
with LABA + ICS that was significantly different to that of LTRA
+ ICS (MD 0.11, 95% CI 0.05 to 0.17) (Analysis 1.10).
Symptom-free days (% change from baseline)
Six studies with 2692 adults reported symptom-free days (Fish
2001;Grosclaude 2003;Nelson 2000;Nelson 2001; Pavord 2007;
Ringdal 2003). The pooled effect estimate showed that the addi-
tion of LABA (salmeterol was used in all of these trials) increased
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the percentage of symptom-free days by 7.27% (95% CI 4.71 to
9.83) compared with LTRA (Analysis 1.11).
Day-time symptom scores (high score is worse) - change
from baseline
Five studies with 3823 adults reported daytime symptom scores
(Fish 2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal
2003). Four of the studies comparing LABA + ICS tomontelukast
+ ICS showed improvement in day-time symptom score with
LABA+ ICS (SMD-0.18, 95%CI -0.25 to -0.12) (Analysis 1.12).
Change in morning symptom scores
As only one adult trial contributed date to this outcome (Ceylan
2004), we were unable to pool data (Analysis 1.13).
Night-time symptom score (5-point scale, higher score is
worse) - change from baseline
As only one trial contributed date to this outcome (Nelson 2001),
we were unable to pool data (Analysis 1.14).
Change in number of night awakenings per week - change
from baseline
Four studies with 4214 adults reported night awakenings (Bjermer
2003; Fish 2001; Ilowite 2004; Nelson 2000). The combined
overall estimate showed that LABA + ICS led to fewer awakenings
than LTRA + ICS (MD -0.12, 95% CI -0.19 to-0.06) (Analysis
1.15).
Change in % of nights with no awakenings per week -
change from baseline
Two studies reported this outcome based on data from 673 adults
(Grosclaude 2003; Nelson 2001) and showed a greater percentage
of awakening-free nights per week with LABA + ICS (MD 6.89%,
95% CI 2.87 to 10.91) (Analysis 1.16).
Change in % rescue-free nights
As only one trial contributed date to this outcome (Grosclaude
2003), we were unable to pool data (Analysis 1.17).
Withdrawals for any reason
Eleven studies involving 6291 adults reported withdrawals due to
any reason. Overall, there was a significant reduction in the risk of
withdrawal with LABA (12%) compared with LTRA (14%) when
added to ICS (RR 0.84, 95% CI 0.74 to 0.96) (Analysis 1.18).
Withdrawals due to adverse effects
Eleven studies in 6291 adults reported withdrawals due to adverse
effects. The overall estimate comparing LABA and ICSwith LTRA
and ICS did not show a significant difference between the groups
(RR 1.01, 95% CI 0.79 to 1.29) (Analysis 1.19).
Withdrawals due to poor asthma control (exacerbations)
Eight studies in 5354 participants reported withdrawals due to
exacerbations. There were no significant differences in the overall
estimate (RR 0.87, 95% CI 0.49 to 1.56; random-effects model)
(Analysis 1.20l).
Patients with one or more exacerbations requiring hospital
admission
Four studies in 3993 adults contributed data for this outcome
(Bjermer 2003; Grosclaude 2003; Ilowite 2004; Ringdal 2003).
There was no significant difference between the two study groups
(RR 1.31, 95% CI 0.58 to 2.98) (Analysis 1.21).
Serious adverse events
Seven studies in 5658 adults reported this outcome. The pooled
result indicated that serious adverse events were significantly more
likely to occur with LABAs (3.4%) than with LTRAs (2.5%) (RR
1.35, 95% CI 1.00 to 1.82; P = 0.05) (Analysis 1.22). This is
shown as a Cates plot in Figure 6, and the number needed to treat
to harm (NNTH) for one additional patient to suffer a serious
adverse event on LABA over 48 weeks was 78 (95% CI 33 to
infinity). The 12-week NNTH for serious adverse events was 236
(95% CI 100 to infinity).
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Figure 6. In the LRTA group 4 people out of 100 had a serious adverse event over 48 weeks, compared to 5
(95% CI 4 to 7) out of 100 for the LABA group. The NNT(H) for one extra patient to suffer a serious adverse
event over 48 weeks with LABA is 78 (95% CI 33 to infinity).
In view of the proposed reasons behind the increased risk of serious
adverse events (SAEs) with LABAs (Cates 2008a; Cates 2008b;
Cates 2009a; Cates 2009b), we undertook a post hoc subgroup
analysis of the pooled estimate by exploring the relationship be-
tween the number of inhaler devices and the risk of SAEs. The risk
ratio of serious adverse events was RR 0.72 (95% CI 0.26 to 1.99)
in the three studies using a single inhaler to deliver both LABA
and ICS, compared to LTRA and ICS, and RR 1.43 (95%CI 1.04
to 1.97) in the four studies in which LABA and ICS were deliv-
ered by separate inhalers (Analysis 2.4). The difference between
the two subgroup estimates did not reach statistical significance,
with a test for subgroup differences giving: Chi² = 1.61, df = 1 (P
= 0.20); I² = 38.1% (Figure 7).
Deaths
One study reported deaths (Bjermer 2003) with no significant
difference between the two study groups (one death occurred in
the LABA group) (Analysis 1.23).
Headache
Ten studies with 6187 adults reported headache as an adverse
event. There was no significant difference in the overall result or
when the two different types of LTRA were compared to LABA
and ICS (RR 1.07, 95% CI 0.9 to 1.26) (Analysis 1.24).
Cardiovascular events
Five studies with 5163 adults reported cardiovascular events
(Bjermer 2003; Fish 2001; Ilowite 2004; Nelson 2000; Ringdal
2003). There was no significant difference when LABA and ICS
was compared to LTRA and ICS (RR 1.09, 95% CI 0.77 to 1.53)
(Analysis 1.25).
Oral moniliasis
Six studies with 5203 adults reported the number of patients with
oral moniliasis. The studies compared LABA and ICS to mon-
telukast and ICS, showing an overall significantly increased risk
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of oral moniliasis with the addition of LABA compared to mon-
telukast + ICS (RR 1.86, 95% CI 1.00 to 3.44) (Analysis 1.26).
Yet, the occurrence rates were low and this represents an average
risk of oral moniliasis of 1% for LABA and 0.5% for LTRA. The
risk difference for this outcome was 0.01 (95% CI 0 to 0.01).
Osteopenia and osteoporosis
Two studies on 2963 adults reported this outcome (Bjermer 2003;
Ilowite 2004) with no significant difference between the study
groups (RR 0.56, 95% CI 0.12 to 2.63) (Analysis 1.27).
Elevated liver enzymes
As only one trial contributed data to this outcome (Bjermer 2003),
we were unable to pool data (Analysis 1.28).
Overall adverse events
Nine studies with 5977 adults reported adverse events, which did
not show a significant difference when LABA and ICS was com-
pared to LTRA and ICS. In fact, the absence of group difference
(RR 1.03, 95% CI 0.99 to 1.07) (Analysis 1.29) met our a priori
definition of equivalence.
Patient treatment satisfaction
Three studies with 2020 adults (Fish 2001; Nelson 2001; Ringdal
2003) reported significantly higher patient satisfaction with LABA
and ICS than with LTRA and ICS (RR 1.12, 95% CI 1.04 to
1.20) (Analysis 1.30). Random-effects modelling was used due to
the high level of statistical heterogeneity (I2 = 61.8%).
Change from baseline in serum eosinophils ( x 10e9/L)
Two adult studies reported this outcome (Bjermer 2003; Ilowite
2004), which showed a statistically significant greater decrease in
serum eosinophils with LTRA + ICS than with LABA + ICS (MD
0.04, 95% CI 0.02 to 0.05) (Analysis 1.31).
D I S C U S S I O N
Primary outcome
Our review has shown that in adult patients who remain symp-
tomatic on low or moderate doses of inhaled steroids, the addition
of a LABA reduces the relative risk of exacerbations requiring oral
steroids compared to the addition of a LTRA. The rate of exac-
erbations requiring oral steroids was 11% in those treated with
a combination of LTRA and ICS compared to 9% with the use
of LABA; an absolute risk reduction of 2%. Thirty-eight patients
need to be treated over 48 weeks with LABA and ICS instead of
LTRA and ICS to avoid one patient from experiencing an exacer-
bation requiring rescue oral steroids. When assessed over 12 weeks
this number is 106.
The results were homogeneous between the trials. The choice of
LTRA did not appear to affect the magnitude of the benefit re-
lated to LABA. When compared to LTRA and ICS, a single in-
haler containing both LABA and ICS was associated with a 50%
reduction in the risk of exacerbations requiring systemic steroids
while a 10% reduction was observed when the two drugs were de-
livered separately. This difference were statistically significant but
should be interpreted cautiously because it is not based on a head-
to-head comparison and may be confounded by other differences
between the trials that used single or separate inhalers (such as
trial duration and ICS dose used). However, the direction of effect
is congruent with findings of head-to-head comparisons of single
versus separate inhalers (Nelson 2003).
The other characteristics we wished to explore to better guide the
selection of treatment for specific patients were similar between
the studies, and thus could not be explored. These were age, dose
of ICS, degree of airway obstruction, choice of LABA, and study
quality. In particular, the absence of paediatric trials contributing
data to this outcome prevented any conclusion with regards to
the relative effect of LABA versus LTRA as add-on to ICS on the
occurrence of exacerbations requiring rescue systemic steroids in
children. Treatment duration did not notably affect the direction
or magnitude of effect.
Secondary outcomes
Statistically significant improvements were seen with LABA and
ICS compared to LTRA and ICS for most secondary outcomes.
The average difference in the improvement from baseline in FEV1
between LABA and LTRA was 80 mL (95% CI 60 to 100 mL),
namely 215 mL with the addition of LABA to ICS compared to
134 mL with the addition of LTRA to ICS. A change of 200 mL
or more in FEV1 is considered a clinically important difference
as it exceeds normal intra-subject variation (ATS 1991). However,
in the absence of a placebo group these changes from baseline
may overestimate an expected improvement as both exceed the
previously reported benefit for the additive effect of each drug in
comparison with the use of ICS alone. Indeed, previous Cochrane
reviews have quantified the magnitude of improvement in FEV1
attributable to each drug over that of ICS and placebo. The addi-
tion of LABA to ICS was associated with an increase of 110 to 120
mL (Ducharme 2010), while an increase of 60 mL was observed
for the combination of LTRA and ICS over ICS alone (Ducharme
2004b). The clinical importance of the observed differences in
favour of LABA over LTRA (80 mL in FEV1, 15 mL in morn-
ing PEF, and 12 mL in evening PEF) is debatable, particularly as
LABA are specifically meant to achieve bronchodilation.
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The outcome measures of rescue-free days, rescue medication use,
asthmaquality of life, symptom-free days, daytime symptom score,
number and per cent of night awakenings, and patient satisfaction
were also statistically significantly better with LABA. Moreover,
significantly fewer patients allocated to the combination of LABA
and ICS withdrew from the study for any reason. Yet, in most
secondary outcomes (other than lung function) the magnitude of
the observed difference appearedmodest. No group difference was
observed in the risk of withdrawals due to poor asthma control
and hospitalisation.
Only two trials examined the impact of both strategies on in-
flammatory markers, namely serum eosinophils. The addition of
a LTRA to ICS was associated with a greater (4%) reduction from
baseline serum eosinophils when compared to LABA and ICS.
The risk of serious adverse events (SAEs) was higher with LABA
than LTRA (3.4% with LABA versus 2.5% with LTRA, a risk
difference of 1%) but at the limit of statistical significance since
the lower limit of the 95% CI equalled the conventional threshold
for statistical significance at the 5% level. The apparent increased
risk of SAEs with LABA should be regarded as a provisional result.
Although the number needed to treat with LABA over 48 weeks
for one additional serious adverse event is 78 (95% CI 33 to in-
finity), the severity of the adverse effects raises concern. We thus
performed a post-hoc analysis to explore whether the use of one
or two devices for delivering LABA and ICS influenced the risk of
severe adverse outcomes. The increased risk may be limited to the
studies using two separate inhalers to deliver LABA and ICS. This
is concordant with accumulating evidence of an increased risk of
SAEs in patients using LABA without ICS and is possibly medi-
ated by non-compliance with concurrent inhaled steroids (Perera
2003). The test for a difference in risk between single and sepa-
rate inhalers did not show a significant difference between these
subgroups (Figure 7).
There was no difference observed between treatments in the risk
of cardiovascular events, headaches, and osteopenia or osteoporo-
sis. Only the risk of oral moniliasis was significantly higher in
the LABA group than the LTRA group, although the risk differ-
ence was clinically small (1% for LABA in comparison with 0.5%
for LTRA). The risk of overall adverse effects was similar in both
groups, meeting our a priori definition of equivalence and suggest-
ing a similar overall safety profile of the two treatment options.
There was no difference between LABA and LTRA in withdrawals
due to adverse effects.
One of the entry criteria common to all included trials was the
need to demonstrate significant reversibility in FEV1 (≥ 12% im-
provement post-bronchodilation). It is possible that the require-
ment to demonstrate a significant reversibility with short-acting
β2−agonists resulted in the selection of patients who were more
likely to show a response on lung function outcomes. This may ex-
plain the greater differences in favour of LABA that were observed
with measures of lung function compared to other outcomes. Al-
though reversibility to a bronchodilator is one of the standard di-
agnostic criteria of asthma (Boulet 2001; BTS 2003; GINA 2009;
USA 2002) only a minority of asthmatic patients display signifi-
cant reversibility at a given point in time (Storms 2003). It is quite
possible that the selection of patients, with significant reversibility,
has favoured the combination of LABA and ICS over LTRA and
ICS.
Themajor limitation of the relevant studies in this area is the strik-
ing absence of large studies examining the best step three in chil-
dren. There remains uncertainty as to whether LABAs are effec-
tive in reducing the requirement for oral steroids in children (Ni
Chroinin 2009b) and a direct comparison of the role of these two
drugs in children is urgently required. One well-designed cross-
over paediatric trial met the eligibility criteria for inclusion in this
review (Lemanske 2010). Unfortunately it reported rescue oral
steroids in the context of a composite outcome which did not fit
our outcome definition and the authors declined to provide the
necessary additional data to allow inclusion of other outcomes in
this review. Several other paediatric trials were excluded as they
tested add-on therapy in children still on step one or in those al-
ready on step three (Stelmach 2007; Stelmach 2008). As wide vari-
ations in the definition of exacerbations have been identified as an
important difficulty in comparing data across studies, the extrac-
tion of data restricted to the use of rescue oral steroids appeared
important. Many asthma guidelines still recommend LABAs as an
add-on therapy in children. In view of the potential harms asso-
ciated with LABAs, it is particularly critical for future paediatric
studies to carefully examine the best option as add-on therapy for
those who remain partially controlled on ICS alone.
The relative homogeneity of adult trials limits the application of
the results in children and patients older than 65 years old, smok-
ers, and thosewith asthmawith no significant reversibility to short-
acting beta2-agonists. Moreover, how well these add-on therapies
perform when added to doses of ICS outside the range of those we
have reviewed remains uncertain. Inadequate documentation and
reporting also limits generalisation of results to adolescents. We
recommend that trialists including adolescents specify the number
included and perform subgroup analyses on this age group to begin
to address this considerable gap in knowledge. An individual data
meta-analysis might provide critical information to determine if
the presence of allergic rhinitis modifies the observed superiority
of LABA over LTRA as add-on therapy to ICS.
With well-documented decreases in adherence over time (Storms
2003), onewonderswhether anundocumented lack of compliance
affected the results. Was there poor adherence to a twice daily regi-
men for LABA?With a flat dose-response curve to inhaled steroids
(Powell 2003), one may even wonder whether similar improve-
ment observed with LTRA and LABA is derived from enhanced
compliance to inhaled steroids per se, as a result of study participa-
tion, rather than the selected add-on therapies. Is the greater im-
provement associated with concomitant rather than separate de-
livery of LABA and ICS mostly attributable to better lung deposi-
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tion of and interaction between both drugs (Buhl 2003; Rosenhall
2003) or better adherence with ICS? In the absence of adherence
measures, these questions remain unanswered. The perception of
more rapid and greater benefit by the patients with LABA is of-
ten regarded by clinicians as justification for selecting LABA over
LTRA as add-on therapy. In the two trials reporting satisfaction,
significantly more patients were satisfied in the group receiving
LABA + ICS (85%) than those treated with LTRA + ICS (76%).
Although derived from close to 6000 patients in six trials, the re-
sults of the primary outcome could be reversed by nine additional
trials of similar size to those included, showing no group differ-
ence. The direction of results may be influenced by patient selec-
tion. It is possible that a differential effect of add-on options may
be influenced by age, airway reversibility, smoking status, severity
of baseline airway obstruction, type of asthma (eosinophilic versus
non-eosinophilic), triggers (such as allergic rhinitis), adherence,
etc. Future studies should now focus on comparing these add-on
strategies in selected groups of patients so that characteristics of
responders to either option may be better delineated. Measures of
adherence (before and after randomisation) should also be incor-
porated in to the design of future studies.
The results apply predominantly to adult asthmatics who remain
symptomatic despite 200 to 1000 µg/day doses of CFC-BDP or
equivalent, and who present with a moderate (baseline FEV1 of
65% to 75% predicted value) reversible airway obstruction. The
results should not be regarded as applicable to children and ado-
lescents, or patients over 65 years of age.
The extensive search strategy yielded the identification and volun-
tary disclosure of data from several relevant trials, including two
high-quality unpublished reports, and reduced the risk of publi-
cation bias. This assessment is also supported by a negative test
for funnel plot asymmetry, although one must acknowledge the
low sensitivity of this test in the presence of few trials. The high
methodological quality of all trials contributing data and the con-
firmation of methodology and extracted data by authors or the
study sponsors for the studies contributing to the primary out-
come strengthen our findings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In asthmatic adults with mild or moderate airway obstruction
who are on low doses of inhaled corticosteroids and who demon-
strate significant reversibility to a short-acting bronchodilator, the
risk of an exacerbation requiring oral corticosteroids over 12 to
48 weeks was 17% lower in participants treated LABA compared
LTRA. This was compatible with a NNT over a 48 week period of
38. Compared to LTRAs, the addition of LABA to inhaled corti-
costeroids is associated with statistically significant improvements
in lung function, symptom-free days, use of rescue β2-agonists,
symptoms, symptom-free days, night awakenings, and quality of
life, although the group differences are generally modest. There
is evidence that LABAs increase the risk of serious adverse events
when compared with LTRAs, from 2.5% to 3.4%. The findings
support the use of a single inhaler for the delivery of LABA and
inhaled corticosteroids. There are insufficient data to conclude
which is the best add-on therapy for children unsatisfactorily con-
trolled on ICS alone.
Implications for research
Future trials should address the main gaps in knowledge, namely
the generalisability of results to the following.
1. Children, adolescents, and elderly patients.
2. Patients with severe (or milder) airway obstruction.
3. Asthmatic patients with minimal or no (< 12%) airway
reversibility to bronchodilators at time of enrolment but with
positive provocation challenge or other convincing criteria of the
diagnosis of asthma.
4. Patients with co-morbidities, such as allergic rhinitis,
aspirin-induced asthma, smokers or having environmental
exposure to cigarette smoke, etc.
5. Add-on therapy to higher dose of inhaled corticosteroids
than 200 to 280 µg/day of HFA-BDP, or equivalent.
6. Monitoring of adherence to both combination therapies.
7. Use of single inhalers for delivery of LABA and ICS
compared to LTRA and ICS
8. Comparison of LABA and LTRA versus LABA and ICS (in
a single device).
9. Measuring and reporting the impact of each adjunct
therapy on inflammatory markers (preferably using induced
sputum) and airway hyper-responsiveness over time.
10. Careful monitoring and reporting of outcomes that are
important to the patient, particularly exacerbations requiring
systemic steroids or hospital admission, symptoms, symptom-
free days, night awakenings, quality of life, satisfaction, and life-
threatening asthma as defined by admission to ICU or requiring
intubation or ventilation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bjermer 2003
Methods Parallel-group, multicentre trial (148 centres in 37 countries)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
LTRA: 638±285 µg of beclomethasone-equivalent/day
LABA: 647±229 µg of beclomethasone-equivalent/day
RANDOMISED: 1490 (LTRA: 747; LABA: 743)
WITHDRAWALS:
LTRA: 125 (17%)
LABA: 110 (15%)
AGE in years: mean ± SD
LTRA: 41.2 ± 13.6
LABA: 41.0± 13.7
GENDER (% male)
LTRA: 45.4%
LABA: 44.8%
SEVERITY:
MODERATE asthma
BASELINE % PRED FEV1
LTRA: 71.3 ± 13.2
LABA: 72.7 ± 13.9
ALLERGIC RHINITIS:
LTRA: 61.7%
LABA: 60.4%
ALLERGEN TRIGGERS:
Not reported
ASTHMA DURATION in years: mean ± SD
LTRA: 16.3 ± 13.0
LABA: 16.2 ± 12.7
ELIGIBILITY CRITERIA: age: 15-72 years; clear history of chronic asthma for at least
1 year; regular use of inhaled corticosteroids over 8 weeks prior to study entry; FEV1
values between 50% and 90% of predicted;≥12% improvement in FEV1 or PEFR after
ß-agonists; minimum pre-determined level of daytime and night-time inhaled short-
acting ß-agonist use (≥ 1 puff/day); minimum asthma symptom score (biweekly score of
≥56 on a scale of 0 to 336); current treatment includes only short-acting beta2-agonists
and inhaled corticosteroids (200-1000 µg/day or equivalent); women with negative urine
pregnancy test at screening
EXCLUSIONCRITERIA: emergency treatment for asthma within 1month of 1st visit;
hospitalisation for asthma within 3 months; unresolved upper respiratory tract infection
within 3 weeks; active sinus infection; received the following asthma medications: oral
corticosteroidswithin 1month, cromolyn, nedocromil, leukotriene-receptor antagonists,
long-acting or oral ß-agonists, inhaled anticholinergics within 2 weeks, theophylline,
terfenadine, fexofenadine, loratadine, or cetirizine within 1 week
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Bjermer 2003 (Continued)
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 4 weeks
Intervention period: 48 weeks
INTERVENTION GROUP 1
LTRA: montelukast @ 10 mg/day p.o. + ICS (FP 100 µg bid, via discus)
INTERVENTION GROUP 2
LABA: salmeterol 50 ug bid, via MDI + ICS (FP 100 µg bid, via Discus)
2 inhalers used for combination therapy.
CO-TREATMENT: none
Outcomes INTENTION-TO-TREAT ANALYSES
Outcomes used at endpoint or 48 weeks
PULMONARY FUNCTION TESTS
Change from baseline FEV; change from baseline in am PEFR
SYMPTOM SCORES
Change from baseline NIGHT-TIME awakenings
**EXACERBATIONS
Exacerbations requiring systemic steroids; exacerbations requiringhospital admission; ex-
acerbations requiring unscheduled office visit; exacerbations requiring emergency room
visit; time to first exacerbation
Definition: an asthma attack was defined by one or all of the following, hospitalisation;
unscheduled office visit; ER visit; CS use (oral, IM, IV or rectal use)
FUNCTIONAL STATUS
Change in quality of life; change in night-time awakenings
INFLAMMATORY MARKERS
Change in serum eosinophils
ADVERSE EFFECTS
Elevated liver enzymes, headache, nausea, death, neutropenia, increased lymphocytes
WITHDRAWALS
Due to adverse effects; due to poor control; overall
(** denotes primary outcome)
Notes Full-text report; additional unpublished data provided by Peter Polos, June 2003
Funder: Merck Frost
Confirmation of methodology and data extraction: received (Peter Polos, June 2003)
User-defined number: 48 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by computer generated
random numbers
Allocation concealment (selection bias) Low risk Allocation occurred at pharmacy and not
conducted by investigator
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Bjermer 2003 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Number coded MDI/tablets supplied by
pharmacy
Tripple-blind (patient, assessor and treat-
ing physician); double-dummy (identical
placebo)
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk Intention-to-treat analysis reported, but
method not available
Selective reporting (reporting bias) Low risk Data obtained from investigators
Other bias Low risk
Ceylan 2004
Methods Parallel-group; single centre study (Turkey)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn
BASELINE INHALED STEROID DOSAGE
Not reported (400µg/d BUD given as standard during 4 week run-in period)
RANDOMISED
48.NBbaseline data only reported for those who completed the study: LTRA: 20; LABA:
20
WITHDRAWALS:
Not stated by treatment group
AGE in years, mean:
LTRA: 33.2
LABA: 39.1
GENDER (% male):
LTRA: 55
LABA: 50
SEVERITY
Moderate persistent asthma
BASELINE % PRED FEV1 (L):
LTRA: 69.7
LABA: 71.2
ALLERGIC RHINITIS (%):
LTRA: 60
LABA: 70
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: Mean ± SD:
LTRA: 8.1± 4
LABA: 9 ± 8.8
ELIGIBILITY CRITERIA: age 15-60 years; diagnosis of asthma (GINA); persistent
asthma symptoms for at least 1 year; use of ICS for at least 6 months; post-run in period:
FEV1 or PEF ≥60 and ≤80% predicted
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Ceylan 2004 (Continued)
-≥15% reversibility increase in FEV1; mean am PEF value ≤85% max after SABA; use
of SABA ≥2 times per day or am/night symptom score ≥2 on 4 or less days per week
EXCLUSION CRITERIA: smokers; pregnant or lactating women; life-threatening
asthma; patients hospitalised due to asthma in last 3 months; upper/lower RTI
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 4 weeks
Intervention period: 8 weeks
Outcomes at 4, 8, and 12 weeks
INTERVENTION GROUP 1
-LTRA = montelukast @ 10 mg/day p.o.+ BUD 200 µg BID, unclear inhaler device
INTERVENTION GROUP 2
-LABA = formoterol 12 µg bid,+ BUD 200 µg BID, unclear inhaler device
CO-TREATMENT:
-SABA prn
Outcomes PULMONARY FUNCTION TESTS
Change in FEV1 % predicted; change in FEV1 (L); change in am PEF*; change in pm
PEF
SYMPTOM SCORES
Morning symptom scores; night symptom scores
EXACERBATIONS
Not reported (participants who exacerbated were excluded from the study)
FUNCTIONAL STATUS
Rescue medication usage (puffs/d); % days without rescue medication usage
INFLAMMATORY MARKERS
Not reported
EXACERBATIONS
Need for a drug not included in the protocol
ADVERSE EFFECTS
Candidiasis; sore throat; voice problems; headache
WITHDRAWALS
Not clear
-Due to ADVERSE EFFECTS
Not reported
-Due to poor control
Not reported
-Overall
Stated
* Main outcome
Notes Full-text report
No funding body
User-defined number: 8 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
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Ceylan 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk Stated ITT for efficacy and safety, however
baseline data are only presented for 40 par-
ticipants who completed the study
Selective reporting (reporting bias) Unclear risk Unable to verify whether primary outcome
measured in the review
Other bias Low risk
ELEVATE
Methods Parallel group, pragmatic randomised controlled study in primary care population in the
UK
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE
Not specified
RANDOMISED:
LTRA: 164
LABA: 176
WITHDRAWALS
Not specified (12 participants withdrew from treatment)
AGE in years: mean ± SD
Not reported
GENDER (% male)
Not reported
SEVERITY
Not described
BASELINE PEF (% predicted)
LTRA: 89.2
LABA: 87
ALLERGEN TRIGGERS
Not reported
ALLERGIC RHINITIS
Not reported
ASTHMA DURATION in years
Not reported
ELIGIBILITY CRITERIA
>11 years; PEF predicted >50%; inadequately controlled on inhaled corticosteroids
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ELEVATE (Continued)
EXCLUSION CRITERIA
Not listed
SETTING: primary care
Interventions DURATION: 2 years
1. LTRA (not specified from abstract)
2. LABA (not specified from abstract)
Outcomes Asthma quality of life (AQLQ); exacerbations; asthma control questionnaire; PEF %
predicted; symptoms; SABA usage; hospital admission; change in ICS (for participants
at step 3)
Notes TJL emailed for data: 22nd April, 2010.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Pragmatic randomised controlled trial
Allocation concealment (selection bias) Low risk Centralised ’ring-in’ centre for randomisa-
tion
Blinding (performance bias and detection
bias)
All outcomes
High risk Single-blind (to study personnel)
Incomplete outcome data (attrition bias)
Exacerbations
Low risk Low withdrawal rates (12/352) unlikely to
affect results
Selective reporting (reporting bias) High risk Study presented as conference abstract.
Outcomes within it well reported, but
no information presented on exacerbations
and SAEs. Trial protocol indicates that ex-
acerbations were measured
Other bias Unclear risk No full-text article presenting clinical end-
points available to determine this
Fish 2001
Methods Parallel-group study, multicentre trial (71 centres in USA and Puerto Rico)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
84-4000 µg of beclomethasone-equivalent/day
RANDOMISED: 948
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Fish 2001 (Continued)
LTRA: 472
LABA: 476
WITHDRAWALS:
LTRA: 70 (15%)
LABA: 61 (13%)
AGE in years: mean ± SD
LTRA: 39.5 ± 14.0
LABA: 39.9 ± 13.5
GENDER (% male)
LTRA: 38%
LABA: 39%
SEVERITY:
Not described
BASELINE FEV1 (% pred)
LTRA: 68.6 (0.4) SE
LABA: 68.1 (0.4) SE
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: %
Less than 10 years
LTRA: 26%
LABA: 24%
Over 10 years
LTRA: 74%
LABA: 76%
ELIGIBILITY CRITERIA: aged ≥15 years; male or non-pregnant, non-lactating fe-
male; asthma for ≥ 6months; symptomatic despite ICS for at least 6 weeks prior to
screening; 50-80% predicted FEV1; ≥12% increase in FEV1 post-bronchodilator (200
µg albuterol)
In the 7 to 14 days prior to randomisation one or more of the following:
1. FEV1 of 50 to 80% of predicted
2. average of 4 or more puffs per day albuterol
3. symptom score of 2 or more for 3 or more days
4. 3 or more nights when patient woke at night due to asthma symptoms
EXCLUSION CRITERIA
Not described
SETTING: outpatients in private and university clinics
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 1-2 weeks
Intervention period: 12 weeks
INTERVENTION GROUP 1
LTRA: montelukast 10 mg qd + ICS: continued current medication (which included
fluticasone, triamcinolone, BDP, BUD and flunisolide) Mean 565 µg in CFC BDP-
equivalent)
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid, via Diskus + ICS: continued current medication
Mean 546 µg in CFC BDP-equivalent
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Fish 2001 (Continued)
2 inhalers used for combination therapy
CO-TREATMENT: none permitted
Outcomes INTENTION-TO-TREAT ANALYSES
Outcomes used at endpoint
PULMONARY FUNCTION TESTS
**Change from baseline in AM PEFR; change from baseline in pm PEFR
SYMPTOM SCORES
Change from baseline overall symptom scores; change in symptom-free days; patient
satisfaction
EXACERBATIONS
Definition: any worsening of asthma symptoms requiring treatment beyond the use of
blinded study drug and/or supplemental albuterol. Patients who experienced an asthma
exacerbation were withdrawn from the study
FUNCTIONAL STATUS
Change from baseline in mean overall use of B2-agonists (puffs/DAY); change from
baseline in mean DAYTIME use of B2-agonists (puffs/DAY); change from baseline in
meanNIGHT-TIMEuse of B2-agonists (puffs/DAY); change in rescue-free days; change
in night-time awakenings
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Drug related and non-drug related
WITHDRAWALS
Due to adverse effects reported
(** denotes primary outcome)
Notes Full-text report
Received additional unpublished data provided by Karen Richardson, GSK, UK, August
2003
Funded by Glaxo Wellcome, studies SMS40003 & SMS40004
Confirmation of methodology and data extraction received
User-defined order: 12 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Methods of randomisation: by computer
generated random number
Allocation concealment (selection bias) Low risk Means of assignment by number coded in-
haler/pills supplied by pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy design
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Fish 2001 (Continued)
Incomplete outcome data (attrition bias)
Exacerbations
Low risk Received additional unpublished data pro-
vided by Karen Richardson, GSK,UK, Au-
gust 2003
Selective reporting (reporting bias) Low risk Primary outcome data available for meta-
analysis
Other bias Low risk
Green 2006
Methods Crossover, single centre study in UK
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
≤400 µg BDP equivalent
N RANDOMISED: 49
N COMPLETED: 39
M = 25
F = 24
MEAN AGE: 42
SEVERITY: not stated
BASELINE FEV1: 74.8%
ATOPIC: 93%
INCLUSION CRITERIA: 18-75 yrs, diagnosed with asthma; receiving treatment with
less than or equal to 400 µg/day CFC-BDP per day ; one or more of 1) >15% increase in
FEV1 post-SABA; 2) >20% within-day variability in PEF assessed twice daily over a 2-
week period; 3) provocative concentration of methacholine causing a 20% fall in FEV1
(PC20) <8 mg/mL-1; following run-in on 200mcg day BUD, participants were eligible
if they had recorded day- or night-time asthma symptoms on their diary cards on at least
4 days in the third or fourth baseline week
EXCLUSION: current smokers or smoking history of >10 pack-yrs, significant comor-
bidity, treated with oral corticosteroids, long-acting ß2-agonists, leukotriene antagonists
or theophylline; asthma exacerbation or lower respiratory tract infection within the 4
weeks prior to trial entry
Interventions LTRA + ICS versus LABA + ICS (Stable low dose of ICS)
INTERVENTION GROUP 1
LTRA: oral montelukast 10 mg qd + budesonide 100 mg BID
INTERVENTION GROUP 2
LABA: formoterol 12 mg BID + budesonide 100 mg BID
TREATMENT PERIOD: 6 weeks (wash-out period: 4 weeks)
RUN-IN PERIOD: 4 weeks
CO-TREATMENT: not reported
Outcomes INTENTION-TO-TREAT ANALYSES: Crossover data analysed for completers
PULMONARY FUNCTION TESTS:
FEV1, PEFRbut only improvements when groups compared, no individual group results
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Green 2006 (Continued)
were presented
SYMPTOM SCORES:
VAS (individual group values not presented, but rather differences between groups)
EXACERBATIONS
Reported as events
FUNCTIONAL STATUS
Not stated
INFLAMMATORY MARKERS
Not stated
ADVERSE EFFECTS
Not stated
WITHDRAWALS
Not reported
Notes Funding source not disclosed
Confirmation of methodology and data extraction received
User-defined order: 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’I believe that this was generated using a com-
puter statistical package generating a random se-
quence. I don’t know the package that was used
and unfortunately the individual has left our or-
ganisation but had extensive clinical trials exper-
tise.’
Allocation concealment (selection bias) Low risk ’...this was indeed generated by a third party,
namely the pharmacist responsible for dispens-
ing the double blindmedication (...)None of the
study investigators were aware of the randomi-
sation schedule until the last patient had com-
pleted the cross-over study’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
High risk Completers used for analysis
Selective reporting (reporting bias) Low risk OCS-treated exacerbations reported.Data could
not be extracted as only data on events and not
number of participants were made available
Other bias Low risk
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Grosclaude 2003
Methods Parallel group, open-label study; multicentre study (115 centres in France)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE
1000 µg CFC Beclomethasone or equivalent daily.
RANDOMISED = 253
LTRA: 130
LABA: 123
WITHDRAWALS
LTRA: 16 (12%)
LABA: 7 (6%)
AGE in years: mean ± SD
LTRA: 44.6 (18.2)
LABA: 43.1 (17.8)
GENDER (% male)
LTRA: 39
LABA: 39
SEVERITY
Not described
BASELINE % PRED FEV1 (L)
Not reported
BASELINE PEF (L/min):
LTRA: 327
LABA: 344
ALLERGIC RHINITIS (%):
LTRA: 51%
LABA: 52%
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: Mean ± SD
Reported as % with asthma duration:
<1 year: 6; between 1 and 5 years: 17; between 5 and 10 years: 15; between 10 and 15
years: 19; more than 15 years: 43
ELIGIBILITY CRITERIA: less than or equal to 15 years of age diagnosed asthma;
treatment for at least four weeks with CFC BDP equivalent of ≥1000 µg/d and inhaled
SABA prn; able to use Mini Wright PEF metre; able to fill in daily record card
Over last seven days of run-in:
1. mean am PEF between 60-80% predicted best (as obtained post-BD at visit 2)
2. asthma symptoms on at least two days
3. used SABA at least four times
EXCLUSION CRITERIA: use of systemic CS, anti-leukotriene agent, LABA, lower
RTI within previous four weeks; hospitalisation within previous 4 weeks; hypersensitiv-
ity to one of compound study drugs; serious uncontrolled concurrent disease; allergen
specific immunotherapy in incremental phase; smoker or ex-smoker with 10 pack year;
participation in clinical study in previous month
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 1-2 weeks
Intervention period: 12 weeks
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Grosclaude 2003 (Continued)
INTERVENTION GROUP 1
LTRA: montelukast @ 10 mg/day p.o.+ CFC BDP 250 ug two puffs bid, via pMDI
INTERVENTION GROUP 2
LABA: salmeterol 50 ug bid, via MDI + FP 250 mcg one puff bid, via diskus (single
combination inhaler)
CO-TREATMENT: SABA prn
Outcomes INTENTION-TO-TREAT ANALYSES outcomes used at endpoint or 12 weeks
PULMONARY FUNCTION TESTS
**change from baseline in AM PEF; change from baseline in pm PEFR
SYMPTOM SCORES
Change from baseline % nights with awakenings; change from baseline in % days with
no symptoms; change from baseline in % nights with no symptoms
EXACERBATIONS
One or more of:
Mild: reduction in AM PEF of >20% of baseline; increased bronchodilator usage; awak-
enings due to asthma on one or more consecutive nights
Moderate: reduction in AM PEF >30% of baseline; change in maintenance therapy or
premature termination of trial therapy; oral steroids
Severe: hospitalisation
FUNCTIONAL STATUS
Change frombaseline in%nights without rescuemedication usage; change frombaseline
in % days without rescue medication usage; % of patients with good asthma control 10
of 12 weeks as defined by presence of two of:
1. PEF ≥80% predicted
2. no more than four puffs of BD on no more than 2 days
3. symptom free for at least two days;
4. presence of all the following criteria on a weekly basis: no nocturnal awakening;
no exacerbation; no unscheduled medical contact; no adverse effect of treatment
leading to withdrawal)
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Headache; gastroenteritis; upper respiratory inflammation; pharyngitis; viral respiratory
infections; malaise and fatigue; allergic rhinitis; diarrhoea; digestive discomfort & pain;
ENT symptoms; muscle cramps and spasms; regurgitation and reflux; nasal inflamma-
tion; vertigo; nausea and vomiting; cough; lower respiratory infections; dyspeptic symp-
toms
WITHDRAWALS
Due to poor completion of diary cards; due to adverse effects; due to poor control
-overall (all reported)
(** denotes primary outcome)
Notes Full-text report and unpublished trial report
Received additional unpublished data (SFCF4007) from GSK website
Funded by GSK
User-defined number: 12 weeks
Risk of bias
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Grosclaude 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 1
Allocation concealment (selection bias) Low risk See Appendix 1
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’The safety population included all sub-
jects who received at least 1 dose of the
study medication. The intent-to-treat pop-
ulation (ITT) included all randomised sub-
jects who received at least one dose of the
study medication, and from whom daily
record card (DRC) data were available dur-
ing the run-in period and the treatment pe-
riod.’
Selective reporting (reporting bias) Low risk Data for exacerbations reported in phar-
maceutical company download. The defi-
nition of exacerbation was not explicit and
we could not used the outcome data for this
study in the meta-analysis
Other bias Low risk
Hendeles 2004
Methods Parallel groups; number of sites and countries unclear
Participants INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn
with history of EIB at baseline
BASELINE INHALED STEROID DOSAGE
Not reported
RANDOMISED = 91 (unclear allocation between groups)
WITHDRAWALS
Not reported
AGE in years (range)
15-60
GENDER (% male)
Not reported
SEVERITY
Not described
BASELINE % PRED FEV1 (L)
LTRA: 81.3
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Hendeles 2004 (Continued)
LABA: 78.9
ALLERGIC RHINITIS (%)
Not reported
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: Mean ± SD
Not reported
ELIGIBILITY CRITERIA: participants with asthma who remained symptomatic on
ICS; age 15-60 years; history of EIB
EXCLUSION CRITERIA: not reported
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION
Intervention period: 4 weeks
INTERVENTION GROUP 1
LTRA: montelukast @ 10 mg/day p.o.+ FP 125 µg one puff bid, via inhalation
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid, via MDI + montelukast placebo + ICS = FP 125 µg one
puff bid, via inhalation (separate inhalers)
CO-TREATMENT
Not reported
Outcomes INTENTION-TO-TREAT ANALYSES: outcomes used at endpoint or 4 weeks
PULMONARY FUNCTION TESTS
Challenge FEV1 % predicted; change in FEV1 % predicted; rescue bronchodilation
SYMPTOM SCORES
Not reported
EXACERBATIONS
Not reported
FUNCTIONAL STATUS
Not reported
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Not reported
WITHDRAWALS
Due to adverse events: not reported
Due to poor control: not reported
Overall: reported
Primary outcome not identified
Notes Unpublished: conference abstract
Funded by Merck
User-defined number: 4 weeks
No data could be used for aggregation
Risk of bias
Bias Authors’ judgement Support for judgement
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Hendeles 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informa-
tion not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Information not available
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk Information not available
Selective reporting (reporting bias) Unclear risk Unable to verify whether primary outcome
measured in the review
Other bias Unclear risk Not enough details about the study could
be ascertained from the abstract available
Ilowite 2004
Methods Parallel-group study, multicentre trial (132 centres in USA for 48 weeks)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE: 220 µg of ICS per day
RANDOMISED = 1473
LTRA: 743
LABA: 730
WITHDRAWALS:
LTRA: 128/743
LABA: 113/730
AGE in years: mean ± SD
LTRA: 39.0 (range 14-73)
LABA: 38.1 (range 15-70)
GENDER (% male)
LTRA: 41.2%
LABA: 37.5%
SEVERITY
Moderate-to-severe persistent asthma
BASELINE FEV1 (% pred)
LTRA: 74.3 ± (SD 11.5)
LABA: 74.3 ± (SD 11.7)
ALLERGEN TRIGGERS
Not reported
ALLERGIC RHINITIS
Not reported
ASTHMA DURATION in years
NS
ELIGIBILITY CRITERIA: age 15-65 years; asthma for ≥1 year; ICS use daily for at
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Ilowite 2004 (Continued)
least 8 weeks prior to first visit; baseline FEV1 of 50 to 90% of predicted
≥12 % change in FEV1 after albuterol, and, in the 14 days prior to randomisation one
or more of the following:
1. asthma symptom that required the use of ß2-agonist medication on average once
per day
2. minimum biweekly daytime symptom score of 56 for a 14-day period)
EXCLUSION CRITERIA: emergency department visit in < 1 month; admission for
asthma in < 3 months; upper respiratory infection in < 3 weeks of 1st visit or during
run-in; pregnant or lactating women; use of LABA within 1 month prior to visit 1;
use < 1 month of oral, intravenous, intramuscular, or intra-articular corticosteroids; use
< 2 weeks of leukotriene antagonist, cromolyn, or nedocromil, use of theophylline in
< 1 week, use in < 2 weeks of oral or inhaled long-acting ß2-agonists or inhaled anti-
cholinergics
SETTING: not described
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 2 weeks
Intervention period: 48 weeks
INTERVENTION GROUP 1
LTRA: montelukast 10 mg once daily + fluticasone 125 µg bid via MDI
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid, via MDI + fluticasone 125 µg bid via MDI
2 inhalers used for combination therapy
CO-TREATMENT: not specified
Outcomes INTENTION-TO-TREAT ANALYSES for patients who received at least one dose of
medication
Outcomes used at endpoint
PULMONARY FUNCTION TESTS:
**Change from baseline in AM PEFR; change from baseline in PM PEFR; change from
baseline in FEV1
SYMPTOM SCORES:
Change from baseline DAYTIME symptom scores; change from baselineNIGHTTIME
symptom scores
EXACERBATIONS
Exacerbations requiring systemic steroids
FUNCTIONAL STATUS
Change from baseline in mean OVERALL use of beta2-agonists (puffs/DAY); change
from baseline in mean DAYTIME use of beta2-agonists (puffs/DAY); change from base-
line in mean NIGHT-TIME use of beta2-agonists (puffs/DAY); % night-time awaken-
ings
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Drug related and non-drug related
WITHDRAWALS
Due to adverse effects reported
(** denotes trials primary outcome)
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Ilowite 2004 (Continued)
Notes Unpublished data
Received full disclosure of unpublished data provided by Peter Polos, March 2004
Funded by Merck & Co
Confirmation with supportive documents received for methodology and data extraction
User-defined number: 48 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was determined by com-
puter generated allocation schedule (block
size 4)
Allocation concealment (selection bias) Low risk Centralised, third party randomisation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ITT
Selective reporting (reporting bias) Low risk Data available for meta-analysis of primary
outcome
Other bias Low risk
Lemanske 2010
Methods Crossover study, multicentre study in USA
Participants INADEQUATELY controlled children on inhaled corticosteroids at baseline
BASELINE INHALED STEROID DOSAGE: 100 µg FP ICS per day during run-in
RANDOMISED: 182
WITHDRAWALS:
25
AGE in years: mean ± SD
11 ± 3
GENDER (% male)
68%
SEVERITY:
Mild-to-moderate asthma
BASELINE FEV1 (% pred)
98%
ALLERGEN TRIGGERS:
+ve aeroallergen test 77%
+ve perennial allergen test 70%
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Lemanske 2010 (Continued)
ALLERGIC RHINITIS
Not reported
ASTHMA DURATION
7 years
ELIGIBILITY CRITERIA: age 6 to 17 years; physician diagnosed mild to moderate
asthma, based on NAEPP criteria; FEV1 predicted >60%; increase in FEV1 >12%
predicted or PC20 12.5mg/mL or less
During run-in children had to exhibit uncontrolled asthma, defined as one or more of:
1. diary-reported symptoms (coughing rated as moderate or severe or wheezing rated
as mild, moderate, or severe)
2. rescue use of reliever medication (two or more puffs per day, or
3. peak flows under 80% predicted
EXCLUSION CRITERIA: corticosteroid treatment within 2 weeks (unless ingested
nasally in which case at discretion of investigator; current or prior use of medications
known to interact with corticosteroids; more than three hospitalizations for asthma in the
past year; lung disease other than asthma; significant medical illness other than asthma;
history of cataracts, glaucoma, or medical disorder associated with adverse effects related
to corticosteroids; uncontrolled gastroesophageal reflux symptoms; significant asthma
exacerbation within 2 weeks of Visit 1 or more than 5 courses of systemic corticosteroids
in the past year; life-threatening asthma exacerbation requiring intubation, mechanical
ventilation, or resulting in a hypoxic seizure in last 5 years; adverse reactions to ICS,
LTRA, or LABA preparations; hyposensitization therapy other than an establishedmain-
tenance regimen (continuous regimen for >3 months); pregnancy or lactation; failure to
practice abstinence or use of an acceptable birth control if of child-bearing potential; in-
ability to perform study procedures; refusal to consent to a genotype evaluation; inability
to ingest the study drug; evidence that the family may be unreliable or nonadherent, or
may move from the clinical center area before trial completion
SETTING: not described
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 2-8 weeks
Intervention period: 48 weeks (3 x 16 weeks)
INTERVENTION GROUP 1
LTRA: montelukast 5 or 10 mg once daily + fluticasone 100 µg bid via DPI
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid, via MDI + fluticasone 100 µg bid via DPI
1 inhaler used for combination therapy
CO-TREATMENT: not specified
Outcomes INTENTION-TO-TREAT ANALYSES No (completers analysed)
PULMONARY FUNCTION TESTS:
Collected as part of a composite outcome (differential response**): FEV1
SYMPTOM SCORES:
Collected as part of a composite outcome (differential response**): symptom-free days
EXACERBATIONS
Collected as part of a composite outcome (differential response**): exacerbations requir-
ing systemic steroids
FUNCTIONAL STATUS
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Lemanske 2010 (Continued)
Quality of life (AQLQ)
INFLAMMATORY MARKERS:
Collected
ADVERSE EFFECTS
Drug related and non-drug related
WITHDRAWALS
Stated
(** denotes trials primary outcome)
Notes Full-text article
Funded by National Heart, Lung, and Blood Institute (HL064307, HL064288,
HL064295, HL064287, HL064305, and HL064313), the National Institute of Allergy
and Infectious Diseases (T32AI007635), and the Clinical Translational Science Award
program of the National Center for Research Resources (UL1-RR025011 [Wisconsin],
UL1-RR025780 [Colorado], and UL1-RR024992 [St. Louis])
Confirmation of data: not obtained
User-defined number: 16 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation sched-
ule:
’The pattern of treatment assignment will
utilize the complete set of orthogonal Latin
squares...’
Allocation concealment (selection bias) Low risk Centralised randomisation. Investigators
dialled into server requesting assignment,
and received a packet numberwhich related
to a medication
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’The drug assignments were masked with
the use of placebo tablets and dummy disk
devices that discharged powder without the
active drug’
’...investigators and the children, along
with their caregivers, will not know which
treatment is being received during each
treatment period.’
Incomplete outcome data (attrition bias)
Exacerbations
High risk Completers analysed (crossover design)
Selective reporting (reporting bias) Low risk Primary outcome analysed as events
Other bias Low risk
51Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nelson 2000
Methods Parallel-group study, multicentre trial (39 centres)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
For the three week run-in period 100 µg twice daily FP (equivalent to 400 µg daily of
beclomethasone)
RANDOMISED: 447
LTRA: 225
LABA: 222
WITHDRAWALS:
LTRA: 30 (13%)
LABA: 24 (11%)
AGE in years: mean ± SD
LTRA: 43 ± 13.7
LABA: 40.2 ± 14.4
GENDER (% male)
LTRA: 40%
LABA: 39%
SEVERITY
Not reported
BASELINE FEV1 (% predicted)
LTRA: 70.8 ± 0.05 (SEM)
LABA: 70.0 ± 0.05
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: %
Under 10 years
LTRA: 23%
LABA: 24%
10 years or more
LTRA: 77%
LABA: 76%
ELIGIBILITY CRITERIA: age ≥15 years; asthma ≥ 6 months; low-moderate dose of
ICS for ≥ 1month CFC-BDP: 252-420 µg/day; BUD 400 µg/day; FP 176- 220 µg/
day; triamcinolone 600 - 800 µg/day); 50-80% of predicted normal
≥12 % increase in FEV1 post-200 µg albuterol;
At randomisation: FEV1 50% to 80% of predicted; 1 additional sign of inadequate
asthma control in the preceding 7 days:
1. ≥ 4 puffs/day albuterol
2. symptom score ≥2 on a scale of (0-5) for ≥ 3 days
3. ≥3 nights waking for asthma
EXCLUSION CRITERIA: pregnant or lactating female patients; life threatening
asthma; hospitalised for asthma in the last three months; significant concurrent diseases;
<30 days of screening: use of theophylline, other bronchodilators, other leukotriene
modifiers, cromolyn or nedocromil
SETTING: not specified
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 3 weeks
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Nelson 2000 (Continued)
Intervention period: 12 weeks
INTERVENTION GROUP 1
LTRA: oral montelukast 10 mg once daily + ICS = FP 100 µg twice daily, via diskus
INTERVENTION GROUP 2
LABA: salmeterol 50 µg twice daily, via Diskus + ICS = FP 100 µg twice daily, via Diskus
1 inhaler used for combination therapy
CO-TREATMENT: none
Outcomes Modified INTENTION-TO-TREAT ANALYSES
Outcomes used at endpoint for exacerbations and withdrawals only (not available for
continuous values)
PULMONARY FUNCTION TESTS
Change from baseline FEV1; change from baseline in AM PEFR; change from baseline
in PM PEFR
SYMPTOM SCORES
Change from baseline OVERALL symptom scores; change from baseline in nighttime
awakenings; change in symptom-free days
EXACERBATIONS
Exacerbations requiring hospital admission; exacerbations requiring systemic steroids
(data provided)
FUNCTIONAL STATUS
Change from baseline in mean OVERALL use of ß2-agonists (puffs/DAY); change in
rescue-free days
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Included oral candidiasis, sore throat, hoarseness, headache
WITHDRAWALS
Due to adverse effects
Due to poor control
Overall
(reported)
(** denotes primary outcome)
Notes Full-text report
Received additional unpublished data provided by Karen Richardson, GSK (July 2003)
Funded by Glaxo Wellcome, study SAS40018
Confirmation of methodology and data extraction received
User-defined order: 12 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation sched-
ule
Allocation concealment (selection bias) Low risk Numbered coded inhaler/pills supplied by
pharmacy
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Nelson 2000 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’The primary population for the analyses
of demographic/baseline characteristics, ef-
ficacy and safety was the Intent-to-Treat
(ITT Population), which consisted of all
subjects who were randomised to receive
study drug.’
Selective reporting (reporting bias) Low risk Data available for primary outcome.
Other bias Low risk
Nelson 2001
Methods Parallel-group, multicentre trial (54 centres)
Participants INADEQUATELY controlled adolescent and adult participants on inhaled glucocorti-
coids at baseline
BASELINE INHALED STEROID DOSAGE:
Not described
RANDOMISED = 429
LTRA: 215
LABA: 214
WITHDRAWALS:
LTRA: 18 (8%)
LABA: 12 (6%)
AGE in years: mean ± SD
LTRA: 39.3 ± 13.20
LABA: 40.9 ± 13.17
GENDER (% male)
LTRA: 44%
LABA: 44%
SEVERITY
Not described
BASELINE FEV1 (% predicted)
LTRA: 65.86 ± 0.58 (SEM)
LABA: 66.62 ± 0.58
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: %
Under 10 years
LTRA: 24%
LABA: 24%
10 years or over
LTRA: 76%
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Nelson 2001 (Continued)
LABA: 76%
ELIGIBILITY CRITERIA: age ≥12 years; asthma ≥ 6 months; FEV1 50-80% of
predicted normal; ≥12 % increase in FEV1 post 200 µg albuterol
Following 7-14 day run-in
In the six days prior to randomisation one or more of the following:
1. an average of 4 or more puffs/day of albuterol
2. a symptom score of 2 or more on at least 2 days for any of the asthma symptom
categories
3. at least one night when the patient woke due to asthma
4. two or more days where pm to am PEF variation was 20% or more
* intake of daily inhaled steroids prior to randomisation is NOT specified as inclusion
criteria*
Patients also must have been using an oral or inhaled SABA for 6 weeks
EXCLUSION CRITERIA: not described
SETTING: clinical centres
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 1-2 weeks
Intervention period: 4 weeks
INTERVENTION GROUP 1
LTRA: zafirlukast 20 mg twice daily + ICS: constant dose of existing ICS medication
INTERVENTION GROUP 2
LABA: salmeterol 42 µg, 2 puffs twice daily via MDI + ICS = constant dose of existing
ICS medication
2 inhalers used for combination therapy
CO-TREATMENT:
Theophylline or other medications that could potentially interact with study treatment
not allowed; Albuterol inhalers provided for use on an as needed basis but all other
bronchodilators not permitted; antihistamines, nasal decongestants and intranasal med-
ications for rhinitis were permitted
Outcomes INTENTION-TO-TREAT ANALYSES: outcomes used at endpoint
PULMONARY FUNCTION TESTS
Change from baseline FEV1; **change from baseline in am PEFR; change from baseline
in PM PEFR; change in PEF variability
SYMPTOM SCORES
Change from baseline DAYTIME symptom scores; change from baseline NIGHT-
TIME symptom scores; change in symptom-free days; patient satisfaction
EXACERBATIONS
Exacerbations requiring systemic steroids; exacerbations defined as any worsening of
asthma symptoms requiring a change in the patients asthma therapy other than increased
use of supplemental albuterol. Patients who experienced an exacerbation were withdrawn
from the study
FUNCTIONAL STATUS
Change from baseline in mean DAYTIME use of B2-agonists (/DAY); change from
baseline in mean NIGHT-TIME use of ß2-agonists (/DAY); change in rescue-free days;
change/absolute in rescue-free nights; change in quality of life; change in night-time
awakenings
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Nelson 2001 (Continued)
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Upper respiratory tract infection, headache, nausea
WITHDRAWALS
Due to adverse effects
Due to poor control
Overall
(reported)
(** denotes primary outcome)
Notes Full-text report
Received additional unpublished data provided by Karen Richardson, GSK
Funded by Glaxo Wellcome, protocols SLGA5024 & SLGA5025
Confirmation of methodology and data extraction received
User-defined order: 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 1
Allocation concealment (selection bias) Low risk See Appendix 1
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’The ITT population included all subjects
who were randomized to study drug.’
Selective reporting (reporting bias) Low risk Data available for primary outcome
Other bias Low risk
Nsouli 2001
Methods Unclear if parallel-group or crossover
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
FP 100-300 or CFC BDP 200-550 or BUD 200-400 or flunisolide 500-1000 or triam-
cinolone 400-1000
RANDOMISED: 30
LTRA: unknown
LABA: unknown
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Nsouli 2001 (Continued)
WITHDRAWALS
Not described
AGE in years: mean ± SD
Not described
GENDER (% male)
Not described
SEVERITY
Not described
BASELINE FEV1 (L OR % PRED)
Not described
ALLERGEN TRIGGERS
Not described
ASTHMA DURATION in years: mean ± SD
Not described
ELIGIBILITY CRITERIA
Not described
EXCLUSION CRITERIA
Not described
SETTING
Not described
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: not described
Intervention period: 8 weeks
INTERVENTION GROUP 1
LTRA: montelukast 10 mg QD pm + ICS (low dose ICS)
INTERVENTION GROUP 2
LABA: salmeterol 50 µg BID + ICS (low dose ICS)
2 inhalers used for combination therapy
CO-TREATMENT
Not reported
Outcomes ANALYSES: not reported
PULMONARY FUNCTION TESTS
FEV1 and FEF25-75
SYMPTOM SCORES
None described
EXACERBATIONS
Not described
FUNCTIONAL STATUS
Quality of life
INFLAMMATORY MARKERS
Not described
ADVERSE EFFECTS
Not described
WITHDRAWALS
Not described
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Nsouli 2001 (Continued)
Notes Abstract
Funding of study unknown
Confirmation of methodology and data extraction not obtained
User-defined order: 8 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; other informationnot
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Information not available
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk Information not available
Selective reporting (reporting bias) Unclear risk Cannot establish this reliably
Other bias Unclear risk Cannot establish this reliably
Pavord 2007
Methods Parallel-group, multicentre study in the UK
Participants BASELINE INHALED STEROID DOSE: up to 400 µg (which BDP or HFA) BDP
equivalent
N SCREENED: 132
N RANDOMISED: 66
N COMPLETED: 54
M = 34
F = 32
MEAN AGE: 35
BASELINE DETAILS: PEF 417 L/min; FEV1 predicted 76%
INCLUSION CRITERIA: 18 to 50 years, non-smokers, receiving a stable dose of up
to 400 µg of beclomethasone dipropionate (presumed CFC-BDP equivalent) a day or
equivalent ICS, requiring further therapy; likelihood of compliance with the protocol
requirements and ability to use an Accuhaler and mini-Wright peak flow meter. Post-run
in: baseline FEV1 61 to 85% predicted; PC20 < 8 mg/ml with methacholine challenge;
at least one of: diary card recording of symptoms on > 4 of the last seven days of the run-
in period; recorded use of relief medication on >2 different days during the last seven
days of the run-in period; period variation in PEF of >10% over last seven days of run
in
EXCLUSION: additional medication other than ICS, SABA or OCS in previous 3
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Pavord 2007 (Continued)
months; acute respiratory infection/exacerbation of asthma within 4 weeks of screen-
ing; recent or significant smoking history; pregnancy/lactation; inadequate contraceptive
methods in women of child-bearing age
Interventions 1. Combination fluticasone/salmeterol 100/50 µg B.I.D
2. Fluticasone 100mcg B.I.D. plus montelukast 10mg O.D.
RUN-IN PERIOD: 2 weeks
TREATMENT PERIOD: 12 weeks
Outcomes INTENTION TO TREAT ANALYSES: no
PULMONARY FUNCTION TEST:
FEV1; am PEF; pm PEF
SYMPTOMS:
Percentages of symptom-free days and nights
FUNCTIONAL STATUS:
Rescue medication use
INFLAMMATORY MARKERS:
Neutrophils, eosinophils, macrophages, lymphocytes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’...consecutively randomised according to
a
pre-defined randomisation list...’
Allocation concealment (selection bias) Low risk ’Treatment allocation was concealed from
the subject, pharmacist, and investigator.’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy design employed
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’All summaries and analyses are for the in-
tention-to-treat population (all subjects re-
ceiving at least one dose of the study drug)
. No imputations were performed for miss-
ing data. Therefore if data were missing for
either baseline or one of the time points, it
was not possible to calculate a change from
baseline. However, all available data have
been used for relevant summaries.’
Some imbalance between the treatment
groups in terms of withdrawal, although
denominators for lung function outcomes
show N randomised
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Pavord 2007 (Continued)
Selective reporting (reporting bias) Low risk The outcomes identified as being those of
interest were presented in the article. Data
on exacerbations were not identified as be-
ing an outcome of interest to the investiga-
tors
Other bias Low risk
Ringdal 2003
Methods Parallel-group, multicentre trial (114 centres in 19 countries)
Participants INADEQUATELY controlled participants on ’moderate or high doses’ of inhaled glu-
cocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
800 µg or more of beclomethasone-equivalent/day (moderate or high dose)
RANDOMISED: 806, 81 excluded due to not meeting eligibility criteria for randomi-
sation
LTRA: 369
LABA: 356
WITHDRAWALS:
LTRA: 37 (10%)
LABA: 19 (5%)
AGE in years: mean ± SD
LTRA: 43 (14-79)
LABA: 43 (15-75)
GENDER (% male)
LTRA: 45%
LABA: 46%
SEVERITY: MODERATE PERSISTENT asthma
BASELINE FEV1 (% PRED)
LTRA: 74.3 ± 16.1
LABA: 75.8 ± 15.3
ALLERGEN TRIGGERS
Not described
ASTHMA DURATION in years: mean ± SD
Not described
ELIGIBILITY CRITERIA: age ≥15 years; moderate persistent asthma as per the ATS
and NAEPP Report 2; using inhaled corticosteroids at moderate or high dose ( 400-
1000 µg/day of CFC-BDP, BUD or flunisolide; or 200-500 µg/day of FP) for at least 4
weeks; history of reversible airway obstruction; ≥15% change in FEV1 after 800 µg of
salbutamol;
At end of run-in:MeanPEF of 50% to < 85%of value in clinic after 400 µg of salbutamol;
cumulative symptom score of ≥8 in past 7 days or ≥4 of the last 7 days of run-in
EXCLUSION CRITERIA: Recent change in asthma medication; respiratory tract in-
fection or admission for asthma in < 4 weeks; intake of oral, depot, or parenteral corti-
costeroids in < 4 weeks or ≥2 occasions in past 12 weeks; cigarette smoking ≥10 pack
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Ringdal 2003 (Continued)
year; pregnancy or lactating women or those likely to become pregnant during study;
FEV1 < 50%
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 4 weeks
Intervention period: 12 weeks plus a 2-week follow up
INTERVENTION GROUP 1
LTRA: montelukast 10 mg/day + ICS: FP 100 ug twice daily, via diskus
INTERVENTION GROUP 2
LABA: salmeterol 50 ug bid + ICS: FP 100 µg twice daily, via Diskus
1 inhaler used for combination therapy.
CO-TREATMENT:
Salbutamol provided for relief of symptoms, no other SABAs permitted
Other oral, parenteral or depot CS not allowed except where documented for treatment
of exacerbations. Other existing asthma treatment allowed at constant dose
Outcomes INTENTION-TO-TREAT ANALYSES: yes, but excluding those who were incorrectly
randomised because they failed major inclusion criteria; outcomes used at endpoint
PULMONARY FUNCTION TESTS
Change from baseline in FEV1; **change from baseline in am PEFR; change from
baseline in pm PEFR
SYMPTOM SCORES
Change in total symptom score; % change in symptom-free days and nights; patient
satisfaction; physician assessment of effectiveness; compliance with study treatment
EXACERBATIONS
Exacerbations requiring systemic steroids; exacerbations requiring hospital admission;
exacerbations defined as MILD: deterioration in asthma requiring a clinically relevant
increase in salbutamol use defined as more than 3 additional inhalations per 24 hour
periodwith respect to baseline formore than2 consecutive days.MODERATE: requiring
oral CS and/or antibiotics. SEVERE: requiring hospitalisation
FUNCTIONAL STATUS
% rescue-free days; % change in use of rescue medication (puffs/day); % symptom-free
days
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Serious adverse events, headache, oral thrush
WITHDRAWALS
Due to adverse effects
Overall
(reported)
(** denotes primary outcome)
Notes Full-text report
Received additional unpublished data provided by Karen Richardson, GSK
Funded by Glaxo SmithKline, study SAS40015
Confirmation of methodology and data extraction received
User-defined order: 12 weeks
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Ringdal 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation sched-
ule
Allocation concealment (selection bias) Low risk Numbered coded inhalers/pills supplied by
pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’The ITT population (SFC: 404 subjects;
FP+montelukast: 401 subjects), which in-
cluded all randomised subjects, was used
for adverse event and concurrent medi-
cation data. The modified ITT popula-
tion (SFC: 356 subjects; FP+montelukast:
369 subjects), which excluded randomised
subjects who did not receive treatment as
well as subjects who were incorrectly ran-
domised, was used for efficacy, demogra-
phy and baseline characteristics data.’
Selective reporting (reporting bias) Low risk Data available for primary outcome
Other bias Low risk
SAM40030
Methods Parallel-group, multicentre trial
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
≤400 µg of BDP/day or equivalent
RANDOMISED: 66
LTRA: 33
LABA: 33
WITHDRAWALS:
LTRA: 4/33 (12.12%)
LABA: 9/33 (27.27%)
AGE in years: mean ± SD
35 years
GENDER (% male)
52%
SEVERITY:
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SAM40030 (Continued)
Mild-moderate
BASELINE FEV1 (% pred)
76%
ALLERGEN TRIGGERS:
Not reported
ALLERGIC RHINITIS:
Not reported
ASTHMA DURATION in years
Not reported
ELIGIBILITY CRITERIA: age 18-50 years; confirmed diagnosis of asthma
-have received constant daily dose of up to 400 mcg of inhaled CFC-BDP or equivalent
in the last 4 weeks
During run-in period: FEV1 61-85% of predicted;≥20% fall in FEV1 onmethacholine
challenge; symptom score of ≥1 on 4/7 days; use of rescue ß2-agonists on ≥2/7 days;
≥10% period variation in PEFR over the last 7 days of run-in
EXCLUSION CRITERIA: intake of asthma medication other than inhaled steroids
or short-acting beta2-agonists in the past 4 weeks; oral steroids in the past 3 months;
respiratory infection within 4 weeks; hospital admission in past 12 months; evidence of
underlying chronic lung disease; smoking history of 10 pack-years or more; pregnant or
lactating women; other chronic diseases; use of LABA or LTRAs within 1 month prior
to visit 1; known intolerance to study drugs or inhaled lactose
SETTING: not described
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: not reported
Intervention period: 12 weeks
INTERVENTION GROUP 1
LTRA: montelukast 10 mg die + fluticasone (Flixotide) 100 bid via MDI
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid via MDI + fluticasone 100 µg bid
(in single MDI: Seretide 50)
1 inhaler used for combination therapy
CO-TREATMENT: not specified
Outcomes Modified INTENTION-TO-TREAT ANALYSES
Outcomes used at 12 weeks or endpoint
PULMONARY FUNCTION TESTS
Change from baseline in AM PEFR (L/min); change from baseline in PM PEFR (L/
min); change from baseline in FEV1 (L)
SYMPTOMS (reported as medians)
Change in symptom-free days; change in symptom-free nights
EXACERBATIONS REQUIRING SYSTEMIC STEROIDS
Not reported
FUNCTIONAL STATUS (reported as medians):
Change from baseline in mean DAYTIME use of ß2-agonists; change from baseline in
mean NIGHT-TIME use of ß2-agonists; change in rescue-free days; change in night-
time awakenings
INFLAMMATORY MARKERS (reported as medians):
63Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SAM40030 (Continued)
Sputum **eosinophils, neutrophils, total cell counts, C-LT, histamine, IL-8
ADVERSE EFFECTS
Reported
WITHDRAWALS
Reported
(** denotes primary outcome)
Notes Unpublished data
Received full disclosure of unpublished data provided by Karen Richardson, GSK (July
2003)
Funded by GSK : study #40030
Confirmation with supportive documents received for methodology and data extraction
obtained from Karen Richardson, GSK, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation schedule
Allocation concealment (selection bias) Low risk Opaque consecutive envelopes containing assessment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical placebo
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk ’The intention-to-treat (ITT) sample was used for
the efficacy and safety analyses. This consisted of all
subjects randomised to and receiving at least one dose
of study medication.’
Selective reporting (reporting bias) Unclear risk Not clear whetherOCS exacerbations collected in the
study
Other bias Low risk
SD-004-0216
Methods Parallel-group study; multicentre trial (49 centres in 6 countries)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids at baseline
BASELINE INHALED STEROID DOSAGE:
400-1000 µg of ICS (not specified)/day
RANDOMISED: 236
LTRA: 118
LABA: 118
WITHDRAWALS:
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SD-004-0216 (Continued)
LTRA: 19/118 (16%)
LABA: 12/118 (10%)
AGE in years: mean ± SD
LTRA: 38.3 ± NS
LABA: 38.1 ± NS
GENDER (% male)
LTRA: 47 %
LABA: 49%
SEVERITY:
Not described
BASELINE FEV1 (% predicted)
LTRA: 72.03 ± SD
LABA: 69.71 ± SD
ALLERGEN TRIGGERS
Not reported
ALLERGIC RHINITIS
Not reported
ASTHMA DURATION in years
LTRA: 10.1 ± SD
LABA: 12.1 ± SD
ELIGIBILITYCRITERIA:Male or female outpatient; age 12-70 years; treated for at least
3 mo with 400-1000 µg of inhaled glucocorticoids (presumed CFC-BDP equivalent)
; asthma diagnosis; FEV1 50-80% predicted; ≥12% reversibility in FEV1 and at least
200 mL after inhalation of 1 mg of terbutaline; smoking history of ≤10 pack years
In the 7 days prior to randomisation one or more of the following:
1. a symptom score of ≥1 on 4 days
2. awakening on ≥ 1 night due to asthma symptoms
3. use of ß2-agonists ≥10 puffs as weekly mean
EXCLUSIONCRITERIA: respiratory infection; clinical obstructive pulmonary disease,
or pulmonary dysfunction other than asthma; pregnant or lactating women; use of LABA
within 1 month prior to visit 1; previous use ever of a leukotriene antagonist; known
intolerance to study drugs or inhaled lactose
SETTING: not described
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in period: 10-14 days
Intervention period: 8 weeks
INTERVENTION GROUP 1
LTRA: zafirlukast 20 mg bid + budesonide 200 µg bid via turbuhaler
INTERVENTION GROUP 2
LABA: formoterol 12 µg bid, via turbohaler + budesonide 200 µg bid via turbuhaler
2 inhalers used for combination therapy
CO-TREATMENT: not specified
Outcomes Modified INTENTION-TO-TREAT ANALYSES for patients who received at least one
dose of medication. Outcomes used at endpoint
PULMONARY FUNCTION TESTS
**Change from baseline in am PEFR; change from baseline in pm PEFR; change from
baseline in FEV1
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SD-004-0216 (Continued)
SYMPTOM SCORES
Change from baseline DAY-TIME symptom scores; change from baseline NIGHT-
TIME symptom scores
EXACERBATIONS
Exacerbations requiring systemic steroids
FUNCTIONAL STATUS
Change from baseline in mean OVERALL use of ß2-agonists (puffs/DAY); change from
baseline in mean DAYTIME use of ß2-agonists (puffs/DAY); change from baseline in
mean NIGHT-TIME use of ß2-agonists (puffs/DAY); % night-time awakenings
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Drug related and non-drug related
WITHDRAWALS
Due to adverse effects reported
(** denotes primary outcome)
Notes Unpublished data
Received full disclosure of unpublished data provided by Roger Metcalf, AstraZeneca,
July 2003
Funded by Astra Zeneca. Report #SD-004CR-0216
Confirmation with supportive documents received for methodology and data extraction
User-defined number: 12 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation presented
Allocation concealment (selection bias) Low risk Opaque consecutive numbered envelopes
containing assignment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy
Incomplete outcome data (attrition bias)
Exacerbations
Unclear risk Analysis described as modified
Selective reporting (reporting bias) Unclear risk Not clear whether the study collected infor-
mation on exacerbations treated with OCS
Other bias Low risk
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Storms 2004
Methods Parallel-group; multicentre study (16 centres in USA)
Participants INADEQUATELY controlled participants on inhaled glucocorticoids and SABA prn
with history of EIB at baseline
BASELINE INHALED STEROID DOSAGE
Not reported
RANDOMISED: 78
LTRA: 39
LABA: 39
WITHDRAWALS
LTRA: 0 (0%); LABA: 2 (5%)
AGE in years: mean:
LTRA: 33.3
LABA: 30
GENDER (% male):
LTRA: 29.2
LABA: 41
SEVERITY
Not described
BASELINE % PRED FEV1 (L)
LTRA: 87.5
LABA: 88.1
ALLERGIC RHINITIS (%)
Not reported
ALLERGEN TRIGGERS
Not reported
ASTHMA DURATION in years: mean ± SD:
LTRA: 17.4 ±11.1
LABA: 19.7 ±12
ELIGIBILITY CRITERIA: age 15-45 years with one year history of asthma; uncon-
trolled asthma on ICS for at least 2 months; treatment at randomisation with only SABA
and ICS; history of EIB (15% drop in FEV1 on ICS, 20% if not on ICS); resting FEV1
≥70% predicted; ≥12% increase in baseline FEV1 post-SABA; requirement for SABA
on ≥3 days of last week of run-in period
EXCLUSION CRITERIA: respiratory infection within last 3 weeks and emergency
asthma care in previous 3 months; systemic corticosteroids in previous month; patients
were required to stop an anti-asthma medication with the exception of ICS two weeks
before first study visit; participants requiring oral steroids during the study were with-
drawn
Interventions LTRA + ICS versus LABA + ICS (stable dose of ICS)
DURATION:
Run-in Period: 1-2 weeks
Intervention Period: 4 weeks
INTERVENTION GROUP 1
LTRA: montelukast @ 10 mg/day p.o.+ placebo salmeterol inhaler + FP 100 µg bid, via
Diskus
INTERVENTION GROUP 2
LABA: salmeterol 50 µg bid via MDI +montelukast placebo + FP 100 µg bid, via Diskus
(separate inhalers)
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Storms 2004 (Continued)
CO-TREATMENT: SABA prn
Outcomes INTENTION-TO-TREAT ANALYSES - outcomes used at endpoint or 4 weeks
PULMONARY FUNCTION TESTS
**Challenge FEV1 % predicted; absolute FEV1 % predicted; fall in FEV1 post-exercise
(%); rescue bronchodilation
SYMPTOM SCORES
Clinic exercise assessment score
EXACERBATIONS
None occurred during the study (requirement for OCS)
FUNCTIONAL STATUS
Not reported
INFLAMMATORY MARKERS
Not reported
ADVERSE EFFECTS
Not reported
WITHDRAWALS
Reported
Due to adverse events: reported
Due to poor control: not reported
Overall: reported
(** denotes primary outcome)
Notes Full-text report
Funded by Merck
User-defined number: 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-dummy LTRA and LABA
Incomplete outcome data (attrition bias)
Exacerbations
Low risk ’A modified intention-to-treat approach
was used for efficacy analyses. For FEV1,
all randomized patients who had challenge-
rescue evaluations at baseline and during
treatment were eligible for analyses. There
was no imputation of missing values, and
prior values were not carried forward.’
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Storms 2004 (Continued)
Selective reporting (reporting bias) Low risk No exacerbations occurred during the
study
Other bias Low risk
BDP: beclomethasone; DPI: dry powder inhaler; FEV1: forced expiratory volume in one second; FP: fluticasone; GSK: GlaxoSmithK-
line; ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LTRA: leukotriene receptor antagonist; MDI: metered dose in-
haler; PEFR: peak expiratory flow; challenge FEV1 % predicted: FEV1 measured post-SABA after 6 minutes exercise on a treadmill
exacerbating heart rate to 80-90% of individual’s predicted maximum.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adinoff 1998 One of the interventions was not LTRA + ICS
Anon 1999 Not an RCT - Montelukast vs. zafirlukast review
Anon 2000 Not an RCT (review)
Anon 2001 Not an RCT (review)
Barnes 1997 Not an RCT (review)
Becker 2000 Not an RCT (Review of montelukast)
Bergmann 2004 One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Bleecker 2006 Combined analysis of two combination therapy trials versus anti-leukotriene agent alone
Borker 2005 No ICS co-treatment in both groups
Brabson 2002 No co-intervention with ICS
Buchvald 2003 Study duration was less than 28 days.
Caffey 2005 No ICS co-treatment in both groups
Calhoun 2001 Non permitted drugs: study compared montelukast vs. placebo with both group receiving ICS and
LABA
Cash 2001 Not an RCT - Commentary on a previously published trial.
Chopra 2005 Comparison between two different LABA + ICS combinations
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(Continued)
Chuchalin 2002 One of the interventions was not LTRA + ICS
Currie 2002 No systematic co-treatment with ICS
Currie 2003a Non permitted drug : salmeterol in both groups
Currie 2003b LTRA in both groups
Currie 2003c Duration of intervention <30 days
Davis 2001 No co-treatment with ICS and LTRA
Dekhuijzen 2002 Not an RCT but a review article
Delaronde 2005 Intervention is educational (not drug)
Dempsey 2000 Single dose intervention (not > 28 days)
Deykin 2007 Comparison of MON/SAL with FP/SAL
Dicpinigaitis 2002 No systematic co-treatment with ICS
Donohue 2001 Review of combination therapies
Dorinsky 2001 No ICS used
Dorinsky 2002 One of the interventions was not LTRA + ICS
Dorinsky 2002a One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid (no ICS in
LTRA group)
Dorinsky 2004 One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid (no ICS in
LTRA group)
Dunn 2001 Review of zafirlukast
Edelman 2000 No co-intervention with ICS
Edin 2002 One of the interventions was not LTRA + ICS
Eliraz 2001 No co-treatment with LTRA - Compares two dry powder inhalers
Eliraz 2002 One of the interventions was not LTRA + ICS
Everden 2002 One of the interventions was not LTRA + ICS
Gabrijelcic 2004 One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
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Giannini 2002 One of the interventions was not LTRA + ICS
Grzelewska 2003 One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Gupta 2007 Study assessed LTRAs in addition to LABAs.
Havlucu 2005 Not an RCT
Horwitz 1998 Not an RCT (Review)
Houghton 2004 Comparison of propellants in formoterol - no ICS in both groups
Inouhe 2007 Single dose study protocol
Jarvis 1998 Not an RCT (Review of zafirlukast)
Jarvis 1999 Not an RCT but a review article on Zafirlukast.
Jenkins 2005 LTRA and LABA not compared as add on to ICS
Jonsson 2004 One of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoid
Kalberg 1999 Retrospective data analysis, not an RCT
Kanniess 2002 No systematic co-treatment with ICS
Kanniess 2002b One of the interventions was not LABA + ICS
Karaman 2007 No prior treatment with ICS.
Kardos 2001 One of the interventions was not LABA + ICS
Keith 2009 Observational study
Kemp 1998 Not an RCT (Review)
Knorr 2001 No consistent co-tx with ICS in all patients (Montelukast vs placebo)
Koenig 2008 Study compared LABA and LTRA without background ICS in either group
Kohrogi 1999 Not an RCT (before and after study)
Laviolette 1999 One of interventions is not LABA + ICS
Lazarus 2001 One of interventions is not LTRA + ICS
Lee 2004 No LTRA and No LABA
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Lee 2005 RCT testing two types of ICS
Leflein 2002 No systematic co-treatment with ICS
Lipworth 2000 Intervention < 28 days (1 week only)
Liu 1996 No consistent co-treatment with ICS
(Zileuton vs. placebo as add-on therapy to ICS)
LOCCS Comparison of Combination therapy with LRTA alone.
Maspero 2008 Study compared LABA and ICS with LTRA alone.
McCarthy 2002 One of the interventions was not LTRA + ICS
Meltzer 2002 No co-treatment with inhaled corticosteroids
Miraglia del Giudice 2007 No prior ICS treatment.
Mitchell 2005 Intervention is educational (not drug)
Molitor 2005 One of the interventions not LTRA
Naedele-Risha 2001 Not a RCT, review of LABA+ICS therapy
Nathan 2000 Good review of add-on therapy to ICS. Not an RCT.
Nathan 2001b Not a RCT, review of antileukotriene agents
Nathan 2005 No direct comparison between LABA and LTRA
Nelson 2004 Both treatment groups received FP and Salmeterol (LTRA tested as add-on to LABA)
O’Sullivan 2003 One of the interventions was not LABA + ICS
Ohbayashi 2009 Investigation of addition of anti-leukotriene to combination inhaled steroid and long-acting beta-agonist
Ollendorf 2000 Not an RCT, but an economic evaluation
Oppenheimer 2008 Study assessed addition of anti-leukotriene (montelukast) in addition to combination LABA and ICS
in asthma
Ortega-Cisneros 1998 No leukotriene antagonists used in intervention
Paterson 1999 No systematic co-treatment with ICS
Pearlman 2002 No consistent co-tx with ICS (FP + S vs Montelukast alone)
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Perez 2000 Not RCT - no control group, all patients treated with montelukast
Peroni 2002 Short duration < 28 days
Peroni 2005 Inadequate duration.
Petermann 2004 Review article
Plaza 2005 Intervention is educational (not drug)
Price 2003 One of the interventions was not LABA + ICS
Riccioni 2002 No systematic co-treatment with ICS
Rickard 1998 No systematic co-treatment with ICS
Rosenhall 2003 One of the interventions is not LTRA + ICS
SAS40036 LTRA administered without an ICS.
SAS40037 LTRA administered without an ICS.
SAS40066 LTRA administered without an ICS.
Serrier 2003 One of the interventions is not LTRA + ICS
Sheth 2002 Second report - cost effectiveness analyses
Sims 2003 Intervention < 28 days
Smith 1998 Not an RCT (Review)
Sorkness 2007 LTRA administered without an ICS.
Stanford 2003 LTRA administered without an ICS.
Stelmach 2001 No consistent co-intervention with ICS (RCT of ICS vs. LABA vs. LTRA )
Stelmach 2002 No consistent co-intervention with ICS (RCT of ICS vs. LABA vs. LTRA vs. nedocromil )
Stelmach 2002a No co-intervention with ICS
Stelmach 2007 Participants were all on combination therapy ICS + LABA prior to enrollment and all controller med-
ication was withdrawn for the 4-week run-in period. Neither before or during the run-in were the
participants on ICS alone prior to randomisation
Stelmach 2008 Participants wereall on combination therapy ICS with either LABA or LTRA prior to enrollment and
were removed from all controller medications for the 4-week run-in period: consequently they were not
on ICS alone prior to enrollment
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Stempel 1998 Not an RCT (Review)
Stempel 2002 Not an RCT (Review)
Stevenson 2005 No LTRA or LABA given.
Terzano 2001 One of the interventions is not LTRA + ICS
Thien 2000 Not an RCT (Review)
Tolley 2002 One of the interventions was not LTRA + ICS
Vaquerizo 2003 One of the interventions was not LABA + ICS
Volovitz 1999 No consistent co-intervention with ICS in all patients (Montelukast vs. beclomethasone )
Warner 2001 Not an RCT (Review)
Wilson 1999 Only 14 days intervention (not >=28 days)
Wilson 2001 Only 14 days intervention (not >= 28 days)
Wytrychowski 2001 Not an RCT - controlled study
Yurdakul 2002 Not truly randomised as eligible patients were allocated to each treatment group according to their
application month to hospital (consecutive alocation not random)
Zarkovic 1998 One of the interventions was not LTRA + ICS
Zimmerman 2002 One of the interventions was not LTRA + ICS
Characteristics of ongoing studies [ordered by study ID]
Fardon 2002
Trial name or title
Methods
Participants
Interventions
Outcomes
Starting date
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Fardon 2002 (Continued)
Contact information
Notes
Fardon 2004
Trial name or title
Methods
Participants
Interventions
Outcomes
Starting date
Contact information
Notes
Price 2001
Trial name or title
Methods
Participants
Interventions
Outcomes
Starting date
Contact information Professor D Price (University of East Anglia, Norwich, NR4 7TJ)
Notes ISSN: N0254145816.
Ruggins 2003
Trial name or title
Methods
Participants
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Ruggins 2003 (Continued)
Interventions
Outcomes
Starting date
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or
more exacerbations requiring
systemic corticosteroids
6 5571 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.71, 0.97]
1.1 Montelukast 10 mg once
daily versus Salmeterol 50 mcg
twice daily
5 5142 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.71, 0.97]
1.2 Zafirlukast 20 mg twice
daily versus Salmeterol 50 mcg
twice daily
1 429 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.29, 2.52]
2 Morning PEF: L/min change
from baseline
11 Mean Difference (Random, 95% CI) 15.36 [11.35, 19.37]
2.1 Montelukast 10 mg once
daily versus Salmeterol 50 mcg
twice daily
8 Mean Difference (Random, 95% CI) 15.91 [13.27, 18.55]
2.2 Zafirlukast 20 mg twice
daily versus salmeterol 50 mcg
or formoterol 9 mg twice daily
2 Mean Difference (Random, 95% CI) 9.66 [-1.40, 20.73]
2.3 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 Mean Difference (Random, 95% CI) 23.8 [10.89, 36.71]
3 Evening PEF: L/min change
from baseline
10 Mean Difference (Random, 95% CI) 12.64 [10.11, 15.17]
3.1 Montelukast 10 mg once
daily versus Salmeterol 50 mcg
twice daily
7 Mean Difference (Random, 95% CI) 13.29 [10.34, 16.23]
3.2 Zafirlukast 20 mg twice
daily versus salmeterol 50 mcg
or formoterol 9 mg twice daily
2 Mean Difference (Random, 95% CI) 8.24 [1.99, 14.50]
3.3 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 Mean Difference (Random, 95% CI) 17.5 [10.16, 24.84]
4 FEV1: L change from baseline 10 Mean Difference (Fixed, 95% CI) 0.08 [0.06, 0.10]
4.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
6 Mean Difference (Fixed, 95% CI) 0.08 [0.06, 0.11]
4.2 Zafirlukast 20mg twice
daily vs. Salmeterol 50 mcg or
Formoterol 9mcg twice daily
2 Mean Difference (Fixed, 95% CI) 0.05 [-0.02, 0.12]
4.3 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
2 Mean Difference (Fixed, 95% CI) 0.0 [-0.09, 0.09]
5 FEV1: L % change from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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5.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Zafirlukast 20mg twice
daily vs. Salmeterol 50 mcg or
Formoterol 9mcg twice daily
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FEV1: % predicted end of
treatment
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Zafirlukast 20mg twice
daily vs. Salmeterol 50 mcg or
Formoterol 9mcg twice daily
0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Montelukast 5 mg once
daily versus formoterol 18mg
twice daily
0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 % fall in FEV1
POST-EXERCISE
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Montelukast 10 mg once
daily versus salmeterol 50 mcg
twice daily
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Zafirlukast 20mg twice
daily versus salmeterol 50 mcg
or formoterol 9mcg twice daily
0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Montelukast 5 mg once
daily versus formoterol 18mg
twice daily
0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Rescue-free days: % change from
baseline
5 2612 Mean Difference (IV, Random, 95% CI) 9.18 [5.39, 12.98]
8.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
4 2183 Mean Difference (IV, Random, 95% CI) 7.33 [4.41, 10.26]
8.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Mean Difference (IV, Random, 95% CI) 15.0 [9.43, 20.57]
9 Rescue medication use: puffs/day
change from baseline
7 4055 Mean Difference (IV, Random, 95% CI) -0.49 [-0.75, -0.24]
9.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
4 3353 Mean Difference (IV, Random, 95% CI) -0.37 [-0.56, -0.19]
9.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg or
Formoterol 9 mg twice daily
2 662 Mean Difference (IV, Random, 95% CI) -0.36 [-0.72, 0.00]
9.3 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 40 Mean Difference (IV, Random, 95% CI) -1.4 [-1.81, -0.99]
10 Change in Global asthma QoL
AQLQ Score (higher is better)
- change from baseline
3 2893 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.05, 0.17]
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10.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
2 2464 Mean Difference (IV, Fixed, 95% CI) 0.09 [0.03, 0.16]
10.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Mean Difference (IV, Fixed, 95% CI) 0.19 [0.02, 0.36]
11 Symptom free days: % change
from baseline
6 Mean Difference (Fixed, 95% CI) 7.27 [4.71, 9.83]
11.1 Montelukast 10 mg once
daily versus Salmeterol 50 mcg
twice daily
5 Mean Difference (Fixed, 95% CI) 5.87 [2.86, 8.87]
11.2 Zafirlukast 20 mg twice
daily versus Salmeterol 50 mcg
twice daily
1 Mean Difference (Fixed, 95% CI) 11.0 [6.10, 15.90]
12 Day-time symptom scores
(high is worse) - change from
baseline
5 3823 Std. Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.25, -0.12]
12.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
4 3394 Std. Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.24, -0.10]
12.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Std. Mean Difference (IV, Fixed, 95% CI) -0.29 [-0.48, -0.10]
13 Morning symptoms - change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Night-time symptom score (5pt
scale, higher score is worse) -
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in number of night
awakenings per week - change
from baseline
4 4214 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.19, -0.06]
15.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
3 3785 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.26, -0.05]
15.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Mean Difference (IV, Fixed, 95% CI) -0.1 [-0.18, -0.02]
16 Change in % of nights with no
awakenings per week - change
from baseline
2 673 Mean Difference (IV, Fixed, 95% CI) 6.89 [2.87, 10.91]
16.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 244 Mean Difference (IV, Fixed, 95% CI) 6.60 [-1.06, 14.26]
79Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Mean Difference (IV, Fixed, 95% CI) 7.0 [2.28, 11.72]
17 Rescue-free nights (%) - change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Withdrawals for any reason 11 6291 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.74, 0.96]
18.1 Montelukast 10mg/day
vs Salmeterol 50ug twice daily
9 5626 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.76, 0.98]
18.2 Zafirlukast 20 mg twice
daily vs Salmeterol 50 mcg
twice daily
2 665 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.40, 1.06]
18.3 Montelukast 10mg/d
versus Formoterol 18mcg/d
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Withdrawals due to adverse
events
11 6291 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.79, 1.29]
19.1 Montelukast 10 mg once
daily versus Salmeterol 50 mcg
twice daily
9 5626 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.78, 1.32]
19.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
2 665 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.41, 2.05]
20 Withdrawals due to poor
asthma control/asthma
exacerbation
8 5354 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.49, 1.56]
20.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
6 4689 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.50, 2.07]
20.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
2 665 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.19, 1.32]
21 Patients with one or more
exacerbations requiring hospital
admission
4 3993 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.58, 2.98]
21.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
4 3993 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.58, 2.98]
22 Serious Adverse events 7 5658 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.00, 1.82]
22.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
6 5229 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.00, 1.83]
22.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 15.96]
23 Death 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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23.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Headache 10 6187 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.90, 1.26]
24.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
7 5482 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.92, 1.29]
24.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
2 665 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.36, 1.57]
24.3 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
25 Cardiovascular events 5 5163 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.77, 1.53]
25.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
5 5163 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.77, 1.53]
26 Oral moniliasis 6 5203 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.00, 3.44]
26.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
5 5163 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.02, 3.61]
26.2 Montelukast 10 mg once
daily versus formoterol 18mg
twice daily
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
27 Osteopenia/osteoporosis 2 2963 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.12, 2.63]
27.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
2 2963 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.12, 2.63]
28 Elevated liver enzymes 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
28.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
29 Overall adverse events 9 5977 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.99, 1.07]
29.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
8 5548 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.99, 1.07]
29.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.81, 1.31]
30 Patient treatment satisfaction 3 2020 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.04, 1.20]
30.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
2 1591 Risk Ratio (M-H, Random, 95% CI) 1.09 [1.05, 1.14]
30.2 Zafirlukast 20 mg twice
daily vs. Salmeterol 50 mcg
twice daily
1 429 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.10, 1.47]
31 Change from baseline in serum
eosinophils (x 10e9/L)
2 2787 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.02, 0.05]
31.1 Montelukast 10 mg once
daily vs. Salmeterol 50 mcg
twice daily
2 2787 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.02, 0.05]
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Comparison 2. Subgroup and sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with one or
more exacerbations requiring
systemic corticosteroids:
number of inhaler devices
6 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
1.1 Single device for LABA +
ICS
2 1252 Risk Ratio (IV, Fixed, 95% CI) 0.49 [0.29, 0.83]
1.2 Two devices for LABA +
ICS
4 4319 Risk Ratio (IV, Fixed, 95% CI) 0.88 [0.75, 1.04]
2 Participants with one or
more exacerbations requiring
systemic corticosteroids: dose
of ICS
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Low dose of ICS 3 2742 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.64, 1.00]
2.2 Medium dose of ICS 1 1452 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.67, 1.08]
2.3 Mixed 1 948 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.50, 1.96]
2.4 Unclear 1 429 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.29, 2.52]
3 Participants with one or
more exacerbations requiring
systemic corticosteroids: study
duration
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 12 weeks or less 4 2629 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.45, 0.96]
3.2 48 weeks 2 2942 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.74, 1.04]
4 Serious adverse effects stratified
by number of inhaler devices
used for LABA + ICS
7 Risk Ratio (IV, Fixed, 95% CI) Subtotals only
4.1 Single device for LABA +
ICS
3 1318 Risk Ratio (IV, Fixed, 95% CI) 0.72 [0.26, 1.99]
4.2 Two devices for LABA +
ICS
4 4340 Risk Ratio (IV, Fixed, 95% CI) 1.43 [1.04, 1.97]
Comparison 3. MD archive from previous review version
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Morning PEF (L/min) - change
from baseline
10 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Evening PEF (L/min) - change
from baseline
9 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 FEV1 (L) - change from baseline 8 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Symptom free days (%) - change
from baseline
5 Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 1 Participants with one or more exacerbations requiring systemic corticosteroids.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 1 Participants with one or more exacerbations requiring systemic corticosteroids
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily
Bjermer 2003 107/743 118/747 38.8 % 0.91 [ 0.72, 1.16 ]
Fish 2001 16/476 16/472 5.3 % 0.99 [ 0.50, 1.96 ]
Ilowite 2004 102/718 123/734 40.1 % 0.85 [ 0.67, 1.08 ]
Nelson 2000 3/222 10/225 3.3 % 0.30 [ 0.08, 1.09 ]
Ringdal 2003 17/404 31/401 10.3 % 0.54 [ 0.31, 0.97 ]
Subtotal (95% CI) 2563 2579 97.7 % 0.83 [ 0.71, 0.97 ]
Total events: 245 (LABA + ICS), 298 (LTRA + ICS)
Heterogeneity: Chi2 = 5.31, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 2.31 (P = 0.021)
2 Zafirlukast 20 mg twice daily versus Salmeterol 50 mcg twice daily
Nelson 2001 6/214 7/215 2.3 % 0.86 [ 0.29, 2.52 ]
Subtotal (95% CI) 214 215 2.3 % 0.86 [ 0.29, 2.52 ]
Total events: 6 (LABA + ICS), 7 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Total (95% CI) 2777 2794 100.0 % 0.83 [ 0.71, 0.97 ]
Total events: 251 (LABA + ICS), 305 (LTRA + ICS)
Heterogeneity: Chi2 = 5.31, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 1.2. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 2 Morning PEF: L/min change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 2 Morning PEF: L/min change from baseline
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily
Bjermer 2003 16.86 (2.397959) 13.3 % 16.86 [ 12.16, 21.56 ]
Fish 2001 13.3 (2.882653) 12.3 % 13.30 [ 7.65, 18.95 ]
Grosclaude 2003 13.2 (5.515306) 7.5 % 13.20 [ 2.39, 24.01 ]
Ilowite 2004 14.2 (3.959184) 10.1 % 14.20 [ 6.44, 21.96 ]
Nelson 2000 16.4 (3.816327) 10.4 % 16.40 [ 8.92, 23.88 ]
Pavord 2007 33.3 (10.0255102) 3.3 % 33.30 [ 13.65, 52.95 ]
Ringdal 2003 16 (3.678571) 10.7 % 16.00 [ 8.79, 23.21 ]
SAM40030 31.9 (10.88776) 2.9 % 31.90 [ 10.56, 53.24 ]
Subtotal (95% CI) 70.4 % 15.91 [ 13.27, 18.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.59, df = 7 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 11.82 (P < 0.00001)
2 Zafirlukast 20 mg twice daily versus salmeterol 50 mcg or formoterol 9 mg twice daily
Nelson 2001 15.8 (3.984694) 10.1 % 15.80 [ 7.99, 23.61 ]
SD-004-0216 4.47 (2.280612) 13.5 % 4.47 [ 0.00, 8.94 ]
Subtotal (95% CI) 23.6 % 9.66 [ -1.40, 20.73 ]
Heterogeneity: Tau2 = 53.64; Chi2 = 6.09, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.71 (P = 0.087)
3 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 23.8 (6.586735) 6.1 % 23.80 [ 10.89, 36.71 ]
Subtotal (95% CI) 6.1 % 23.80 [ 10.89, 36.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.00030)
Total (95% CI) 100.0 % 15.36 [ 11.35, 19.37 ]
Heterogeneity: Tau2 = 25.79; Chi2 = 28.25, df = 10 (P = 0.002); I2 =65%
Test for overall effect: Z = 7.51 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.66, df = 2 (P = 0.26), I2 =25%
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Analysis 1.3. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 3 Evening PEF: L/min change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 3 Evening PEF: L/min change from baseline
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily
Fish 2001 8.8 (1.413265) 15.5 % 8.80 [ 6.03, 11.57 ]
Grosclaude 2003 12.2 (2.617347) 10.7 % 12.20 [ 7.07, 17.33 ]
Ilowite 2004 14 (2.122449) 12.6 % 14.00 [ 9.84, 18.16 ]
Nelson 2000 11.8 (1.767857) 14.0 % 11.80 [ 8.34, 15.26 ]
Pavord 2007 22.7 (9.87244898) 1.6 % 22.70 [ 3.35, 42.05 ]
Ringdal 2003 17 (1.803571) 13.9 % 17.00 [ 13.47, 20.53 ]
SAM40030 18.9 (5.056122) 4.9 % 18.90 [ 8.99, 28.81 ]
Subtotal (95% CI) 73.1 % 13.29 [ 10.34, 16.23 ]
Heterogeneity: Tau2 = 8.62; Chi2 = 16.42, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 8.85 (P < 0.00001)
2 Zafirlukast 20 mg twice daily versus salmeterol 50 mcg or formoterol 9 mg twice daily
Nelson 2001 10.6 (1.987245) 13.1 % 10.60 [ 6.71, 14.49 ]
SD-004-0216 3.92 (4.135204) 6.4 % 3.92 [ -4.18, 12.02 ]
Subtotal (95% CI) 19.6 % 8.24 [ 1.99, 14.50 ]
Heterogeneity: Tau2 = 11.79; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 2.58 (P = 0.0098)
3 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 17.5 (3.747449) 7.3 % 17.50 [ 10.16, 24.84 ]
Subtotal (95% CI) 7.3 % 17.50 [ 10.16, 24.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
Total (95% CI) 100.0 % 12.64 [ 10.11, 15.17 ]
Heterogeneity: Tau2 = 8.75; Chi2 = 23.18, df = 9 (P = 0.01); I2 =61%
Test for overall effect: Z = 9.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.70, df = 2 (P = 0.16), I2 =46%
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Analysis 1.4. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 4 FEV1: L change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 4 FEV1: L change from baseline
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Bjermer 2003 0.08 (0.03061225) 0.08 [ 0.02, 0.14 ]
Ilowite 2004 0.07 (0.01530612) 0.07 [ 0.04, 0.10 ]
Nelson 2000 0.15 (0.04081633) 0.15 [ 0.07, 0.23 ]
Pavord 2007 0.11 (0.10714286) 0.11 [ -0.10, 0.32 ]
Ringdal 2003 0.11 (0.03061225) 0.11 [ 0.05, 0.17 ]
SAM40030 0.08 (0.09693878) 0.08 [ -0.11, 0.27 ]
Subtotal (95% CI) 0.08 [ 0.06, 0.11 ]
Heterogeneity: Chi2 = 4.25, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 7.19 (P < 0.00001)
2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily
Nelson 2001 0.03 (0.04081633) 0.03 [ -0.05, 0.11 ]
SD-004-0216 0.11 (0.07142857) 0.11 [ -0.03, 0.25 ]
Subtotal (95% CI) 0.05 [ -0.02, 0.12 ]
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
3 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 0 (0) 0.0 [ 0.0, 0.0 ]
Green 2006 0 (0.047449) 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 0.0 [ -0.09, 0.09 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 0.08 [ 0.06, 0.10 ]
Heterogeneity: Chi2 = 8.85, df = 8 (P = 0.36); I2 =10%
Test for overall effect: Z = 7.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.66, df = 2 (P = 0.16), I2 =45%
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Analysis 1.5. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 5 FEV1: L % change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 5 FEV1: L % change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Storms 2004 34 1.7 (9.5) 36 10.9 (8.5) -9.20 [ -13.43, -4.97 ]
2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily
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Analysis 1.6. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 6 FEV1: % predicted end of treatment.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 6 FEV1: % predicted end of treatment
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Storms 2004 34 91.2 (10.1) 36 86.6 (11) 4.60 [ -0.34, 9.54 ]
2 Zafirlukast 20mg twice daily vs. Salmeterol 50 mcg or Formoterol 9mcg twice daily
3 Montelukast 5 mg once daily versus formoterol 18mg twice daily
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Analysis 1.7. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 7 % fall in FEV1 POST-EXERCISE.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 7 % fall in FEV1 POST-EXERCISE
Study or subgroup LABA +ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily versus salmeterol 50 mcg twice daily
Storms 2004 34 10.5 (10) 36 7.7 (8.1) 2.80 [ -1.48, 7.08 ]
2 Zafirlukast 20mg twice daily versus salmeterol 50 mcg or formoterol 9mcg twice daily
3 Montelukast 5 mg once daily versus formoterol 18mg twice daily
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Analysis 1.8. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 8 Rescue-free days: % change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 8 Rescue-free days: % change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Ringdal 2003 337 32 (38.55) 326 28 (41.53) 20.1 % 4.00 [ -2.10, 10.10 ]
Fish 2001 451 27.4 (34) 443 20.1 (29.5) 27.8 % 7.30 [ 3.13, 11.47 ]
Nelson 2000 196 32.7 (39.2) 189 23 (37.12) 15.6 % 9.70 [ 2.08, 17.32 ]
Grosclaude 2003 117 40.4 (30.9) 124 29.8 (32.6) 14.6 % 10.60 [ 2.58, 18.62 ]
Subtotal (95% CI) 1101 1082 78.0 % 7.33 [ 4.41, 10.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 4.92 (P < 0.00001)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
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(. . . Continued)
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nelson 2001 214 27 (32.2) 215 12 (26.4) 22.0 % 15.00 [ 9.43, 20.57 ]
Subtotal (95% CI) 214 215 22.0 % 15.00 [ 9.43, 20.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.27 (P < 0.00001)
Total (95% CI) 1315 1297 100.0 % 9.18 [ 5.39, 12.98 ]
Heterogeneity: Tau2 = 8.97; Chi2 = 7.85, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.70, df = 1 (P = 0.02), I2 =82%
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Analysis 1.9. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 9 Rescue medication use: puffs/day change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 9 Rescue medication use: puffs/day change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Fish 2001 451 -1.9 (2.12) 443 -1.66 (2.32) 15.2 % -0.24 [ -0.53, 0.05 ]
Ringdal 2003 337 -0.98 (1.84) 326 -0.78 (1.26) 16.3 % -0.20 [ -0.44, 0.04 ]
Nelson 2000 196 -1.86 (2.24) 189 -1.3 (2.06) 12.3 % -0.56 [ -0.99, -0.13 ]
Ilowite 2004 702 -1.66 (1.59) 709 -1.15 (1.6) 17.6 % -0.51 [ -0.68, -0.34 ]
Subtotal (95% CI) 1686 1667 61.4 % -0.37 [ -0.56, -0.19 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.03, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 3.93 (P = 0.000086)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg or Formoterol 9 mg twice daily
Nelson 2001 214 -1.46 (1.9) 215 -0.95 (1.47) 14.6 % -0.51 [ -0.83, -0.19 ]
SD-004-0216 117 -1.86 (1.84) 116 -1.73 (1.83) 11.4 % -0.13 [ -0.60, 0.34 ]
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(. . . Continued)
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 331 331 26.0 % -0.36 [ -0.72, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 1.94 (P = 0.052)
3 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 20 -1.9 (0.5) 20 -0.5 (0.8) 12.6 % -1.40 [ -1.81, -0.99 ]
Subtotal (95% CI) 20 20 12.6 % -1.40 [ -1.81, -0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.64 (P < 0.00001)
Total (95% CI) 2037 2018 100.0 % -0.49 [ -0.75, -0.24 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 29.10, df = 6 (P = 0.00006); I2 =79%
Test for overall effect: Z = 3.84 (P = 0.00012)
Test for subgroup differences: Chi2 = 20.64, df = 2 (P = 0.00), I2 =90%
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Analysis 1.10. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 10 Change in Global asthma QoL AQLQ Score (higher is better) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Ilowite 2004 647 0.9 (0.76) 655 0.78 (0.77) 55.1 % 0.12 [ 0.04, 0.20 ]
Bjermer 2003 581 0.76 (0.96) 581 0.71 (0.96) 31.2 % 0.05 [ -0.06, 0.16 ]
Subtotal (95% CI) 1228 1236 86.3 % 0.09 [ 0.03, 0.16 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0052)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 214 0.76 (0.88) 215 0.57 (0.88) 13.7 % 0.19 [ 0.02, 0.36 ]
Subtotal (95% CI) 214 215 13.7 % 0.19 [ 0.02, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 1442 1451 100.0 % 0.11 [ 0.05, 0.17 ]
Heterogeneity: Chi2 = 2.07, df = 2 (P = 0.35); I2 =3%
Test for overall effect: Z = 3.42 (P = 0.00062)
Test for subgroup differences: Chi2 = 1.09, df = 1 (P = 0.30), I2 =8%
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Analysis 1.11. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 11 Symptom free days: % change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 11 Symptom free days: % change from baseline
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily
Fish 2001 7.98 (2.44898) 28.5 % 7.98 [ 3.18, 12.78 ]
Grosclaude 2003 9.3 (4.209184) 9.6 % 9.30 [ 1.05, 17.55 ]
Nelson 2000 1.1 (3.607143) 13.1 % 1.10 [ -5.97, 8.17 ]
Pavord 2007 13.2 (7.5) 3.0 % 13.20 [ -1.50, 27.90 ]
Ringdal 2003 3 (3.040816) 18.5 % 3.00 [ -2.96, 8.96 ]
Subtotal (95% CI) 72.7 % 5.87 [ 2.86, 8.87 ]
Heterogeneity: Chi2 = 5.00, df = 4 (P = 0.29); I2 =20%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 Zafirlukast 20 mg twice daily versus Salmeterol 50 mcg twice daily
Nelson 2001 11 (2.5) 27.3 % 11.00 [ 6.10, 15.90 ]
Subtotal (95% CI) 27.3 % 11.00 [ 6.10, 15.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
Total (95% CI) 100.0 % 7.27 [ 4.71, 9.83 ]
Heterogeneity: Chi2 = 8.07, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 5.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.06, df = 1 (P = 0.08), I2 =67%
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Analysis 1.12. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 12 Day-time symptom scores (high is worse) - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 12 Day-time symptom scores (high is worse) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Nelson 2000 197 -0.59 (0.7) 191 -0.47 (0.69) 10.2 % -0.17 [ -0.37, 0.03 ]
Ringdal 2003 341 -0.97 (1.11) 330 -0.88 (1.27) 17.6 % -0.08 [ -0.23, 0.08 ]
Fish 2001 451 -0.52 (0.64) 445 -0.42 (0.63) 23.5 % -0.16 [ -0.29, -0.03 ]
Ilowite 2004 711 -0.66 (0.8) 728 -0.48 (0.81) 37.6 % -0.22 [ -0.33, -0.12 ]
Subtotal (95% CI) 1700 1694 88.8 % -0.17 [ -0.24, -0.10 ]
Heterogeneity: Chi2 = 2.56, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.96 (P < 0.00001)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 214 -0.39 (0.58) 215 -0.24 (0.44) 11.2 % -0.29 [ -0.48, -0.10 ]
Subtotal (95% CI) 214 215 11.2 % -0.29 [ -0.48, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
Total (95% CI) 1914 1909 100.0 % -0.18 [ -0.25, -0.12 ]
Heterogeneity: Chi2 = 3.92, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 5.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.36, df = 1 (P = 0.24), I2 =27%
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Analysis 1.13. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 13 Morning symptoms - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 13 Morning symptoms - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 20 -2.6 (0.7) 20 -0.8 (0.6) -1.80 [ -2.20, -1.40 ]
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Analysis 1.14. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 14 Night-time symptom score (5pt scale, higher score is worse) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 214 -0.43 (0.59) 215 -0.25 (0.59) -0.18 [ -0.29, -0.07 ]
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Analysis 1.15. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 15 Change in number of night awakenings per week - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 15 Change in number of night awakenings per week - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Fish 2001 451 -1.42 (2.76) 443 -1.32 (3.16) 2.8 % -0.10 [ -0.49, 0.29 ]
Ilowite 2004 709 -1.02 (1.33) 727 -0.79 (1.35) 21.8 % -0.23 [ -0.37, -0.09 ]
Bjermer 2003 724 -1.74 (1.61) 731 -1.68 (1.62) 15.2 % -0.06 [ -0.23, 0.11 ]
Subtotal (95% CI) 1884 1901 39.7 % -0.16 [ -0.26, -0.05 ]
Heterogeneity: Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.98 (P = 0.0029)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2000 214 -0.19 (0.44) 215 -0.09 (0.44) 60.3 % -0.10 [ -0.18, -0.02 ]
Subtotal (95% CI) 214 215 60.3 % -0.10 [ -0.18, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
Total (95% CI) 2098 2116 100.0 % -0.12 [ -0.19, -0.06 ]
Heterogeneity: Chi2 = 3.15, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.41), I2 =0.0%
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Analysis 1.16. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 16 Change in % of nights with no awakenings per week - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 16 Change in % of nights with no awakenings per week - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Grosclaude 2003 118 26.4 (31) 126 19.8 (30) 27.5 % 6.60 [ -1.06, 14.26 ]
Subtotal (95% CI) 118 126 27.5 % 6.60 [ -1.06, 14.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 214 15 (26.3) 215 8 (23.5) 72.5 % 7.00 [ 2.28, 11.72 ]
Subtotal (95% CI) 214 215 72.5 % 7.00 [ 2.28, 11.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0037)
Total (95% CI) 332 341 100.0 % 6.89 [ 2.87, 10.91 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00078)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.17. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 17 Rescue-free nights (%) - change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 17 Rescue-free nights (%) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Grosclaude 2003 119 26.6 (35.1) 124 24.5 (34.8) 2.10 [ -6.69, 10.89 ]
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
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Analysis 1.18. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 18 Withdrawals for any reason.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 18 Withdrawals for any reason
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10mg/day vs Salmeterol 50ug twice daily
Storms 2004 2/39 0/39 0.1 % 5.00 [ 0.25, 100.89 ]
Ringdal 2003 19/404 37/401 8.3 % 0.51 [ 0.30, 0.87 ]
Nelson 2000 24/222 30/225 6.6 % 0.81 [ 0.49, 1.34 ]
Grosclaude 2003 7/123 16/130 3.5 % 0.46 [ 0.20, 1.09 ]
SAM40030 9/33 4/33 0.9 % 2.25 [ 0.77, 6.59 ]
Fish 2001 61/476 70/472 15.6 % 0.86 [ 0.63, 1.19 ]
Ilowite 2004 113/730 128/743 28.2 % 0.90 [ 0.71, 1.13 ]
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(. . . Continued)
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bjermer 2003 110/743 125/747 27.7 % 0.88 [ 0.70, 1.12 ]
Pavord 2007 9/33 4/33 0.9 % 2.25 [ 0.77, 6.59 ]
Subtotal (95% CI) 2803 2823 91.8 % 0.86 [ 0.76, 0.98 ]
Total events: 354 (LABA + ICS), 414 (LTRA + ICS)
Heterogeneity: Chi2 = 13.41, df = 8 (P = 0.10); I2 =40%
Test for overall effect: Z = 2.22 (P = 0.026)
2 Zafirlukast 20 mg twice daily vs Salmeterol 50 mcg twice daily
Nelson 2001 12/214 18/215 4.0 % 0.67 [ 0.33, 1.36 ]
SD-004-0216 12/118 19/118 4.2 % 0.63 [ 0.32, 1.24 ]
Subtotal (95% CI) 332 333 8.2 % 0.65 [ 0.40, 1.06 ]
Total events: 24 (LABA + ICS), 37 (LTRA + ICS)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
3 Montelukast 10mg/d versus Formoterol 18mcg/d
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (LABA + ICS), 0 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3135 3156 100.0 % 0.84 [ 0.74, 0.96 ]
Total events: 378 (LABA + ICS), 451 (LTRA + ICS)
Heterogeneity: Chi2 = 14.66, df = 10 (P = 0.14); I2 =32%
Test for overall effect: Z = 2.61 (P = 0.0089)
Test for subgroup differences: Chi2 = 1.19, df = 1 (P = 0.27), I2 =16%
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Analysis 1.19. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 19 Withdrawals due to adverse events.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 19 Withdrawals due to adverse events
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily versus Salmeterol 50 mcg twice daily
Storms 2004 1/39 0/39 0.4 % 3.00 [ 0.13, 71.46 ]
Fish 2001 13/476 13/472 11.0 % 0.99 [ 0.46, 2.12 ]
Nelson 2000 6/222 4/225 3.3 % 1.52 [ 0.43, 5.31 ]
Grosclaude 2003 3/123 5/130 4.1 % 0.63 [ 0.15, 2.60 ]
SAM40030 2/33 4/33 3.4 % 0.50 [ 0.10, 2.55 ]
Ringdal 2003 13/404 19/401 16.0 % 0.68 [ 0.34, 1.36 ]
Ilowite 2004 32/730 20/743 16.6 % 1.63 [ 0.94, 2.82 ]
Bjermer 2003 36/743 38/747 31.8 % 0.95 [ 0.61, 1.49 ]
Pavord 2007 2/33 4/33 3.4 % 0.50 [ 0.10, 2.55 ]
Subtotal (95% CI) 2803 2823 89.9 % 1.02 [ 0.78, 1.32 ]
Total events: 108 (LABA + ICS), 107 (LTRA + ICS)
Heterogeneity: Chi2 = 6.96, df = 8 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 7/214 7/215 5.9 % 1.00 [ 0.36, 2.82 ]
SD-004-0216 4/118 5/118 4.2 % 0.80 [ 0.22, 2.91 ]
Subtotal (95% CI) 332 333 10.1 % 0.92 [ 0.41, 2.05 ]
Total events: 11 (LABA + ICS), 12 (LTRA + ICS)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
Total (95% CI) 3135 3156 100.0 % 1.01 [ 0.79, 1.29 ]
Total events: 119 (LABA + ICS), 119 (LTRA + ICS)
Heterogeneity: Chi2 = 7.08, df = 10 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.20. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 20 Withdrawals due to poor asthma control/asthma exacerbation.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 20 Withdrawals due to poor asthma control/asthma exacerbation
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Storms 2004 0/39 0/39 0.0 [ 0.0, 0.0 ]
Fish 2001 19/476 18/472 1.05 [ 0.56, 1.97 ]
Grosclaude 2003 1/123 3/130 0.35 [ 0.04, 3.34 ]
Nelson 2000 2/222 10/225 0.20 [ 0.04, 0.91 ]
Ilowite 2004 9/730 4/743 2.29 [ 0.71, 7.40 ]
Bjermer 2003 19/743 11/747 1.74 [ 0.83, 3.62 ]
Subtotal (95% CI) 2333 2356 1.02 [ 0.50, 2.07 ]
Total events: 50 (LABA + ICS), 46 (LTRA + ICS)
Heterogeneity: Tau2 = 0.32; Chi2 = 8.84, df = 4 (P = 0.07); I2 =55%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 3/214 6/215 0.50 [ 0.13, 1.98 ]
SD-004-0216 3/118 6/118 0.50 [ 0.13, 1.95 ]
Subtotal (95% CI) 332 333 0.50 [ 0.19, 1.32 ]
Total events: 6 (LABA + ICS), 12 (LTRA + ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Total (95% CI) 2665 2689 0.87 [ 0.49, 1.56 ]
Total events: 56 (LABA + ICS), 58 (LTRA + ICS)
Heterogeneity: Tau2 = 0.26; Chi2 = 11.24, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =25%
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Analysis 1.21. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 21 Patients with one or more exacerbations requiring hospital admission.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 21 Patients with one or more exacerbations requiring hospital admission
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Grosclaude 2003 0/119 0/127 0.0 [ 0.0, 0.0 ]
Ringdal 2003 1/404 2/401 0.50 [ 0.05, 5.45 ]
Ilowite 2004 5/718 3/734 1.70 [ 0.41, 7.10 ]
Bjermer 2003 7/743 5/747 1.41 [ 0.45, 4.41 ]
Total (95% CI) 1984 2009 1.31 [ 0.58, 2.98 ]
Total events: 13 (LABA + ICS), 10 (LTRA + ICS)
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 22 Serious Adverse events.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 22 Serious Adverse events
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Fish 2001 5/476 5/472 7.0 % 0.99 [ 0.29, 3.40 ]
Ringdal 2003 4/404 7/401 9.9 % 0.57 [ 0.17, 1.92 ]
Nelson 2000 1/222 2/225 2.8 % 0.51 [ 0.05, 5.55 ]
Ilowite 2004 27/730 22/743 30.6 % 1.25 [ 0.72, 2.17 ]
Bjermer 2003 55/743 34/747 47.6 % 1.63 [ 1.07, 2.46 ]
Pavord 2007 2/33 0/33 0.7 % 5.00 [ 0.25, 100.32 ]
Subtotal (95% CI) 2608 2621 98.6 % 1.35 [ 1.00, 1.83 ]
Total events: 94 (LABA + ICS), 70 (LTRA + ICS)
Heterogeneity: Chi2 = 4.40, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 1/214 1/215 1.4 % 1.00 [ 0.06, 15.96 ]
Subtotal (95% CI) 214 215 1.4 % 1.00 [ 0.06, 15.96 ]
Total events: 1 (LABA + ICS), 1 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 2822 2836 100.0 % 1.35 [ 1.00, 1.82 ]
Total events: 95 (LABA + ICS), 71 (LTRA + ICS)
Heterogeneity: Chi2 = 4.45, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.83), I2 =0.0%
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Analysis 1.23. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 23 Death.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 23 Death
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Bjermer 2003 1/743 0/747 3.02 [ 0.12, 73.92 ]
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Analysis 1.24. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 24 Headache.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 24 Headache
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Ringdal 2003 12/404 18/401 7.4 % 0.66 [ 0.32, 1.36 ]
Nelson 2000 20/222 10/225 4.1 % 2.03 [ 0.97, 4.23 ]
Fish 2001 48/476 44/472 18.2 % 1.08 [ 0.73, 1.60 ]
Grosclaude 2003 1/123 4/130 1.6 % 0.26 [ 0.03, 2.33 ]
SAM40030 1/33 1/33 0.4 % 1.00 [ 0.07, 15.33 ]
Bjermer 2003 93/743 90/747 36.9 % 1.04 [ 0.79, 1.36 ]
Ilowite 2004 71/730 60/743 24.4 % 1.20 [ 0.87, 1.67 ]
Subtotal (95% CI) 2731 2751 93.0 % 1.09 [ 0.92, 1.29 ]
Total events: 246 (LABA + ICS), 227 (LTRA + ICS)
Heterogeneity: Chi2 = 6.70, df = 6 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.99 (P = 0.32)
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(. . . Continued)
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 6/214 11/215 4.5 % 0.55 [ 0.21, 1.46 ]
SD-004-0216 6/118 5/118 2.1 % 1.20 [ 0.38, 3.82 ]
Subtotal (95% CI) 332 333 6.6 % 0.75 [ 0.36, 1.57 ]
Total events: 12 (LABA + ICS), 16 (LTRA + ICS)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.76 (P = 0.45)
3 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 1/20 1/20 0.4 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 0.4 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (LABA + ICS), 1 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 3083 3104 100.0 % 1.07 [ 0.90, 1.26 ]
Total events: 259 (LABA + ICS), 244 (LTRA + ICS)
Heterogeneity: Chi2 = 8.60, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 0.94, df = 2 (P = 0.63), I2 =0.0%
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Analysis 1.25. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 25 Cardiovascular events.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 25 Cardiovascular events
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Fish 2001 4/476 8/472 13.2 % 0.50 [ 0.15, 1.64 ]
Ringdal 2003 6/404 9/401 14.8 % 0.66 [ 0.24, 1.84 ]
Nelson 2000 3/222 1/225 1.6 % 3.04 [ 0.32, 29.01 ]
Ilowite 2004 22/730 18/743 29.3 % 1.24 [ 0.67, 2.30 ]
Bjermer 2003 31/743 25/747 41.0 % 1.25 [ 0.74, 2.09 ]
Total (95% CI) 2575 2588 100.0 % 1.09 [ 0.77, 1.53 ]
Total events: 66 (LABA + ICS), 61 (LTRA + ICS)
Heterogeneity: Chi2 = 3.82, df = 4 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 26 Oral moniliasis.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 26 Oral moniliasis
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Fish 2001 1/476 0/472 3.3 % 2.97 [ 0.12, 72.84 ]
Nelson 2000 3/222 4/225 25.8 % 0.76 [ 0.17, 3.36 ]
Ringdal 2003 3/404 1/401 6.5 % 2.98 [ 0.31, 28.51 ]
Ilowite 2004 13/730 6/743 38.6 % 2.21 [ 0.84, 5.77 ]
Bjermer 2003 7/743 3/747 19.4 % 2.35 [ 0.61, 9.04 ]
Subtotal (95% CI) 2575 2588 93.5 % 1.92 [ 1.02, 3.61 ]
Total events: 27 (LABA + ICS), 14 (LTRA + ICS)
Heterogeneity: Chi2 = 1.88, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
2 Montelukast 10 mg once daily versus formoterol 18mg twice daily
Ceylan 2004 1/20 1/20 6.5 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 6.5 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (LABA + ICS), 1 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 2595 2608 100.0 % 1.86 [ 1.00, 3.44 ]
Total events: 28 (LABA + ICS), 15 (LTRA + ICS)
Heterogeneity: Chi2 = 2.08, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 1.27. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 27 Osteopenia/osteoporosis.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 27 Osteopenia/osteoporosis
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Ilowite 2004 0/730 1/743 33.2 % 0.34 [ 0.01, 8.31 ]
Bjermer 2003 2/743 3/747 66.8 % 0.67 [ 0.11, 4.00 ]
Total (95% CI) 1473 1490 100.0 % 0.56 [ 0.12, 2.63 ]
Total events: 2 (LABA + ICS), 4 (LTRA + ICS)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 28 Elevated liver enzymes.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 28 Elevated liver enzymes
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Bjermer 2003 27/727 24/729 1.13 [ 0.66, 1.94 ]
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Analysis 1.29. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 29 Overall adverse events.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 29 Overall adverse events
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Nelson 2000 117/222 119/225 6.4 % 1.00 [ 0.84, 1.19 ]
Ringdal 2003 176/404 170/401 9.3 % 1.03 [ 0.88, 1.20 ]
Grosclaude 2003 43/123 45/130 2.4 % 1.01 [ 0.72, 1.42 ]
Fish 2001 297/476 279/472 15.3 % 1.06 [ 0.95, 1.17 ]
SAM40030 19/33 21/33 1.1 % 0.90 [ 0.61, 1.34 ]
Bjermer 2003 538/743 530/747 28.8 % 1.02 [ 0.96, 1.09 ]
Ilowite 2004 588/730 576/743 31.1 % 1.04 [ 0.99, 1.10 ]
Pavord 2007 19/33 21/33 1.1 % 0.90 [ 0.61, 1.34 ]
Subtotal (95% CI) 2764 2784 95.5 % 1.03 [ 0.99, 1.07 ]
Total events: 1797 (LABA + ICS), 1761 (LTRA + ICS)
Heterogeneity: Chi2 = 1.42, df = 7 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 84/214 82/215 4.5 % 1.03 [ 0.81, 1.31 ]
Subtotal (95% CI) 214 215 4.5 % 1.03 [ 0.81, 1.31 ]
Total events: 84 (LABA + ICS), 82 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 2978 2999 100.0 % 1.03 [ 0.99, 1.07 ]
Total events: 1881 (LABA + ICS), 1843 (LTRA + ICS)
Heterogeneity: Chi2 = 1.42, df = 8 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 1.30. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 30 Patient treatment satisfaction.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 30 Patient treatment satisfaction
Study or subgroup LABA +ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Ringdal 2003 375/404 335/401 44.3 % 1.11 [ 1.06, 1.17 ]
Fish 2001 337/400 306/386 38.6 % 1.06 [ 0.99, 1.14 ]
Subtotal (95% CI) 804 787 82.9 % 1.09 [ 1.05, 1.14 ]
Total events: 712 (LABA +ICS), 641 (LTRA + ICS)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 3.98 (P = 0.000070)
2 Zafirlukast 20 mg twice daily vs. Salmeterol 50 mcg twice daily
Nelson 2001 152/214 120/215 17.1 % 1.27 [ 1.10, 1.47 ]
Subtotal (95% CI) 214 215 17.1 % 1.27 [ 1.10, 1.47 ]
Total events: 152 (LABA +ICS), 120 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.0013)
Total (95% CI) 1018 1002 100.0 % 1.12 [ 1.04, 1.20 ]
Total events: 864 (LABA +ICS), 761 (LTRA + ICS)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.23, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Chi2 = 3.85, df = 1 (P = 0.05), I2 =74%
0.5 0.7 1 1.5 2
Favours LTRA + ICS Favours LABA + ICS
109Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.31. Comparison 1 Long-acting ß2-agonists + ICS versus leukotriene receptor antagonists + ICS,
Outcome 31 Change from baseline in serum eosinophils (x 10e9/L).
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 1 Long-acting 2-agonists + ICS versus leukotriene receptor antagonists + ICS
Outcome: 31 Change from baseline in serum eosinophils (x 10e9/L)
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Montelukast 10 mg once daily vs. Salmeterol 50 mcg twice daily
Bjermer 2003 693 -0.01 (0.27) 699 -0.04 (0.27) 49.0 % 0.03 [ 0.00, 0.06 ]
Ilowite 2004 690 0.01 (0.26) 705 -0.03 (0.27) 51.0 % 0.04 [ 0.01, 0.07 ]
Total (95% CI) 1383 1404 100.0 % 0.04 [ 0.02, 0.05 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00053)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Subgroup and sensitivity analyses, Outcome 1 Participants with one or more
exacerbations requiring systemic corticosteroids: number of inhaler devices.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 1 Participants with one or more exacerbations requiring systemic corticosteroids: number of inhaler devices
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Single device for LABA + ICS
Ringdal 2003 17/404 31/401 83.1 % 0.54 [ 0.31, 0.97 ]
Nelson 2000 3/222 10/225 16.9 % 0.30 [ 0.08, 1.09 ]
Subtotal (95% CI) 626 626 100.0 % 0.49 [ 0.29, 0.83 ]
Total events: 20 (LABA + ICS), 41 (LTRA + ICS)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Two devices for LABA + ICS
Nelson 2001 6/214 7/215 2.3 % 0.86 [ 0.29, 2.52 ]
Fish 2001 16/476 16/472 5.8 % 0.99 [ 0.50, 1.96 ]
Bjermer 2003 107/743 118/747 46.0 % 0.91 [ 0.72, 1.16 ]
Ilowite 2004 102/718 123/734 45.9 % 0.85 [ 0.67, 1.08 ]
Subtotal (95% CI) 2151 2168 100.0 % 0.88 [ 0.75, 1.04 ]
Total events: 231 (LABA + ICS), 264 (LTRA + ICS)
Heterogeneity: Chi2 = 0.29, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 4.34, df = 1 (P = 0.04), I2 =77%
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Analysis 2.2. Comparison 2 Subgroup and sensitivity analyses, Outcome 2 Participants with one or more
exacerbations requiring systemic corticosteroids: dose of ICS.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 2 Participants with one or more exacerbations requiring systemic corticosteroids: dose of ICS
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low dose of ICS
Bjermer 2003 107/743 118/747 74.1 % 0.91 [ 0.72, 1.16 ]
Nelson 2000 3/222 10/225 6.3 % 0.30 [ 0.08, 1.09 ]
Ringdal 2003 17/404 31/401 19.6 % 0.54 [ 0.31, 0.97 ]
Subtotal (95% CI) 1369 1373 100.0 % 0.80 [ 0.64, 1.00 ]
Total events: 127 (LABA + ICS), 159 (LTRA + ICS)
Heterogeneity: Chi2 = 5.05, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Medium dose of ICS
Ilowite 2004 102/718 123/734 100.0 % 0.85 [ 0.67, 1.08 ]
Subtotal (95% CI) 718 734 100.0 % 0.85 [ 0.67, 1.08 ]
Total events: 102 (LABA + ICS), 123 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 Mixed
Fish 2001 16/476 16/472 100.0 % 0.99 [ 0.50, 1.96 ]
Subtotal (95% CI) 476 472 100.0 % 0.99 [ 0.50, 1.96 ]
Total events: 16 (LABA + ICS), 16 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
4 Unclear
Nelson 2001 6/214 7/215 100.0 % 0.86 [ 0.29, 2.52 ]
Subtotal (95% CI) 214 215 100.0 % 0.86 [ 0.29, 2.52 ]
Total events: 6 (LABA + ICS), 7 (LTRA + ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Chi2 = 0.39, df = 3 (P = 0.94), I2 =0.0%
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Analysis 2.3. Comparison 2 Subgroup and sensitivity analyses, Outcome 3 Participants with one or more
exacerbations requiring systemic corticosteroids: study duration.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 3 Participants with one or more exacerbations requiring systemic corticosteroids: study duration
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 weeks or less
Fish 2001 16/476 16/472 25.1 % 0.99 [ 0.50, 1.96 ]
Nelson 2000 3/222 10/225 15.5 % 0.30 [ 0.08, 1.09 ]
Nelson 2001 6/214 7/215 10.9 % 0.86 [ 0.29, 2.52 ]
Ringdal 2003 17/404 31/401 48.5 % 0.54 [ 0.31, 0.97 ]
Subtotal (95% CI) 1316 1313 100.0 % 0.65 [ 0.45, 0.96 ]
Total events: 42 (LABA + ICS), 64 (LTRA + ICS)
Heterogeneity: Chi2 = 3.46, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.19 (P = 0.029)
2 48 weeks
Bjermer 2003 107/743 118/747 49.2 % 0.91 [ 0.72, 1.16 ]
Ilowite 2004 102/718 123/734 50.8 % 0.85 [ 0.67, 1.08 ]
Subtotal (95% CI) 1461 1481 100.0 % 0.88 [ 0.74, 1.04 ]
Total events: 209 (LABA + ICS), 241 (LTRA + ICS)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Chi2 = 1.93, df = 1 (P = 0.16), I2 =48%
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Analysis 2.4. Comparison 2 Subgroup and sensitivity analyses, Outcome 4 Serious adverse effects stratified
by number of inhaler devices used for LABA + ICS.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 2 Subgroup and sensitivity analyses
Outcome: 4 Serious adverse effects stratified by number of inhaler devices used for LABA + ICS
Study or subgroup LABA + ICS LTRA + ICS Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Single device for LABA + ICS
Ringdal 2003 4/404 7/401 70.1 % 0.57 [ 0.17, 1.92 ]
Nelson 2000 1/222 2/225 18.2 % 0.51 [ 0.05, 5.55 ]
Pavord 2007 2/33 0/33 11.6 % 5.00 [ 0.25, 100.32 ]
Subtotal (95% CI) 659 659 100.0 % 0.72 [ 0.26, 1.99 ]
Total events: 7 (LABA + ICS), 9 (LTRA + ICS)
Heterogeneity: Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Two devices for LABA + ICS
Nelson 2001 1/214 1/215 1.3 % 1.00 [ 0.06, 15.96 ]
Fish 2001 5/476 5/472 6.7 % 0.99 [ 0.29, 3.40 ]
Bjermer 2003 55/743 34/747 58.9 % 1.63 [ 1.07, 2.46 ]
Ilowite 2004 27/730 22/743 33.1 % 1.25 [ 0.72, 2.17 ]
Subtotal (95% CI) 2163 2177 100.0 % 1.43 [ 1.04, 1.97 ]
Total events: 88 (LABA + ICS), 62 (LTRA + ICS)
Heterogeneity: Chi2 = 1.00, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 1.61, df = 1 (P = 0.20), I2 =38%
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Analysis 3.1. Comparison 3 MD archive from previous review version, Outcome 1 Morning PEF (L/min) -
change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 3 MD archive from previous review version
Outcome: 1 Morning PEF (L/min) - change from baseline
Study or subgroup LABA +ICS LTRA +ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nelson 2001 214 28.8 (45.4) 214 13 (36.6) 15.80 [ 7.99, 23.61 ]
SD-004-0216 117 33.86 (63.71) 116 29.39 (63.87) 4.47 [ -11.91, 20.85 ]
Grosclaude 2003 119 44.2 (43.63) 127 31 (42.82) 13.20 [ 2.39, 24.01 ]
SAM40030 33 61.5 (37.3) 33 29.6 (50.2) 31.90 [ 10.56, 53.24 ]
Fish 2001 476 35 (44.6) 472 21.7 (44.2) 13.30 [ 7.65, 18.95 ]
Ilowite 2004 646 55 (71.17) 651 40.8 (71.44) 14.20 [ 6.44, 21.96 ]
Ringdal 2003 288 42 (42.43) 279 26 (45.1) 16.00 [ 8.79, 23.21 ]
Bjermer 2003 725 34.59 (45.77) 732 17.73 (45.72) 16.86 [ 12.16, 21.56 ]
Nelson 2000 197 29.6 (37.89) 190 13.2 (37.22) 16.40 [ 8.92, 23.88 ]
Ceylan 2004 20 54.3 (15.1) 20 30.5 (25.3) 23.80 [ 10.89, 36.71 ]
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Analysis 3.2. Comparison 3 MD archive from previous review version, Outcome 2 Evening PEF (L/min) -
change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 3 MD archive from previous review version
Outcome: 2 Evening PEF (L/min) - change from baseline
Study or subgroup LABA + ICS LTR + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ceylan 2004 20 44.5 (23.3) 20 27 (24.1) 17.50 [ 2.81, 32.19 ]
SAM40030 33 40 (44.8) 33 21.1 (37) 18.90 [ -0.92, 38.72 ]
Ilowite 2004 564 47.4 (71.25) 579 33.4 (72.19) 14.00 [ 5.68, 22.32 ]
Fish 2001 451 27.8 (42.5) 444 19 (42.1) 8.80 [ 3.26, 14.34 ]
Nelson 2000 197 21.8 (35.09) 191 10 (34.55) 11.80 [ 4.87, 18.73 ]
Grosclaude 2003 119 37.4 (40.36) 127 25.2 (41.7) 12.20 [ 1.94, 22.46 ]
Ringdal 2003 271 37 (41.16) 250 20 (41.11) 17.00 [ 9.93, 24.07 ]
Nelson 2001 213 21.8 (43.8) 213 11.2 (38) 10.60 [ 2.81, 18.39 ]
SD-004-0216 117 24.02 (63.6) 116 20.1 (62.68) 3.92 [ -12.29, 20.13 ]
-100 -50 0 50 100
Favours LTRA + ICS Favours LABA + ICS
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Analysis 3.3. Comparison 3 MD archive from previous review version, Outcome 3 FEV1 (L) - change from
baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 3 MD archive from previous review version
Outcome: 3 FEV1 (L) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
SD-004-0216 117 0.22 (0.54) 116 0.11 (0.54) 0.11 [ -0.03, 0.25 ]
Nelson 2001 214 0.26 (0.44) 215 0.23 (0.44) 0.03 [ -0.05, 0.11 ]
Ceylan 2004 20 0.36 (0) 20 0.19 (0) 0.0 [ 0.0, 0.0 ]
Ilowite 2004 602 0.18 (0.25) 621 0.11 (0.25) 0.07 [ 0.04, 0.10 ]
Bjermer 2003 695 0.19 (0.53) 688 0.11 (0.52) 0.08 [ 0.02, 0.14 ]
Ringdal 2003 364 0.28 (0.38) 355 0.17 (0.38) 0.11 [ 0.05, 0.17 ]
SAM40030 33 0.39 (0.36) 33 0.31 (0.43) 0.08 [ -0.11, 0.27 ]
Nelson 2000 197 0.35 (0.42) 195 0.2 (0.42) 0.15 [ 0.07, 0.23 ]
-0.5 -0.25 0 0.25 0.5
Favours LTRA + ICS Favours LABA + ICS
117Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 MD archive from previous review version, Outcome 4 Symptom free days (%) -
change from baseline.
Review: Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Comparison: 3 MD archive from previous review version
Outcome: 4 Symptom free days (%) - change from baseline
Study or subgroup LABA + ICS LTRA + ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fish 2001 451 24.1 (31.9) 445 16.12 (40.8) 7.98 [ 3.18, 12.78 ]
Grosclaude 2003 117 42.7 (31.3) 125 33.4 (34.2) 9.30 [ 1.05, 17.55 ]
Nelson 2000 197 25.1 (36.49) 191 24 (34.55) 1.10 [ -5.97, 8.17 ]
Nelson 2001 214 20 (29.3) 215 9 (22) 11.00 [ 6.10, 15.90 ]
Ringdal 2003 341 38 (38.78) 330 35 (39.96) 3.00 [ -2.96, 8.96 ]
-20 -10 0 10 20
Favours LTRA + ICS Favours LABA + ICS
A D D I T I O N A L T A B L E S
Table 1. Search history
Years Detail
All years to January 2004 Citations: 184 (181 from the literature search and three unpublished trials provided by pharmaceu-
tical companies for a total of 184 citations)
Citations excluded: 172: (1) duplicate citations (N=29), (2) abstracts of considered full-text publi-
cations or secondary analyses of the same study (N = 18), (3) not a randomised controlled trial (N =
72), (4) protocol of ongoing trial (N=1), (5) no consistent co-treatment with inhaled glucocorticoids
(N = 21), (6) one of the tested interventions was not daily LTRA (N = 18), (7) one of the tested
interventions was not daily LABA (N= 5), (8) interventions were administered for less than 4 weeks
(N = 6), and (9) use of prohibited co-interventions such as LABA in both groups (N=2).
Studies meeting the entry criteria of the review: 12 (six full-text publications (Bjermer 2003; Fish
2001; Ilowite 2004; Nelson 2000; Nelson 2001; Ringdal 2003), two unpublished full-text reports
(Hultquist 2000; McCarthy 2003) and four abstracts (Gold (abs) 2001; Green (abs) 2002; Leibman
(abs) 2002; Nsouli 2001). The abstracts did not provide data in sufficient detail to contribute to
the meta-analyses
January 2004 to January 2006 Citations: 60.
Citations excluded: 55: the study was a duplicate (i.e. identical citation of one trial report, or a
subsequent report of a trial) (N = 22); the study was not randomised (N = 2); the study was
ongoing (N = 5); the administration of either LTRA or LABA was not standardised across treatment
groups (N = 3); there was no consistent co-treatment with inhaled glucocorticoids (N = 8); one
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Table 1. Search history (Continued)
of the tested interventions was not daily LTRA as add-on to inhaled glucocorticoids (N = 9); one
of the tested interventions was not daily LABA as add-on to inhaled glucocorticoids (N = 2); the
tested interventions were administered for less than 4 weeks (N = 1); the study used prohibited co-
intervention (i.e., maintenance oral steroids, theophylline, non-steroidal anti-inflammatory drugs,
anticholinergics) (N = 3)
Table 2. ICS at CFC-BDP equivalent dose (µg/day)
Study Actual dose of ICS (total
per day)
CFC- BDP equivalent /
day
Population Low/medium/high
Bjermer 2003 200mcg fluticasone 400mcg Adults Low
Ceylan 2004 400mcg budesonide 400mcg Adults Low
Fish 2001 Range of doses between
175 to 1700mcg
560µg (range 175-1700) Adults Mixed
Gold 2001 100mcg fluticasone 200mcg Adults Low
Green 2006 200mcg budesonide 200mcg Adults Low
Grosclaude 2003 1000mcg CFC BDP and
fluticasone 500mcg
1000mcg Adults High
Hendeles 2004 250mcg fluticasone 500mcg Adults Medium
Ilowite 2004 250mcg fluticasone 500mcg Adults Medium
Lemanske 2010 200mcg fluticasone 400mcg Children Low
Nelson 2000 200mcg fluticasone 400mcg Adults Low
Nelson 2001 not specified requested from author 08/
03
Adults Unclear
Nsouli 2001 Unclear 500mcg Adults Unclear
Pavord 2007 200mcg fluticasone 400mcg Adults Low
Ringdal 2003 200mcg fluticasone 400mcg Adults Low
SAM40030 200mcg fluticasone 400mcg Adults Low
SD-004-0216 400mcg budesonide 400mcg Adults Low
ELEVATE Unclear Unclear Adults Unclear
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Table 2. ICS at CFC-BDP equivalent dose (µg/day) (Continued)
Storms 2004 200mcg fluticasone 400mcg Adults Low
A P P E N D I C E S
Appendix 1. GSK randomisation procedures
The procedures for randomising GSK sponsored studies has been detailed in correspondence between Richard Follows and TL, the
details of which are given below:
The randomisation software is a computer-generated, centralised programme (RandAll). After verification that the randomisation
sequence is suitable for the study design (crossover, block or stratification), Clinical Supplies then package the treatments according
the randomisation list generated. Concealment of allocation is maintained by a third party, since the sites phone in and are allocated
treatments on that basis. Alternatively a third party may dispense the drug at the sites. Unblinding of data for interim analyses can only
be done through RandAll, and are restricted so that only those reviewing the data are unblinded to treatment group allocation.
WH A T ’ S N E W
Last assessed as up-to-date: 16 March 2010.
Date Event Description
5 July 2011 Amended Clarification made to abstract regarding subgroup analysis.
H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 1, 2005
Date Event Description
2 February 2011 New citation required and conclusions have changed Full risk of bias assessment has been incorporated into
the review
Data on secondary outcomes were provided by the new
studies. Serious adverse events are more common with
LABA and ICS than LTRA and ICS. This result is not
definitive and could be influenced by separate adminis-
tration of LABA and ICS
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(Continued)
17 March 2010 New search has been performed Literature search re-run. Three new studies were included
(Lemanske 2010; Pavord 2007; ELEVATE). One previ-
ously included study was excluded (Stelmach 2008); this
study had not contributed data to the primary outcome
4 August 2008 Amended Converted to new review format.
20 June 2006 New citation required and conclusions have changed Five new studies met the entry criteria of the review
(Ceylan 2004; Grosclaude 2003; Hendeles 2004; Stel-
mach 2008a; Storms 2004). Of these, two studies con-
tributed data to this updated review. The additional data
did not alter the conclusions of the review
C O N T R I B U T I O N S O F A U T H O R S
Francine MDucharme reviewed the protocol design; supervised the literature search; reviewed all citations; participated in the selection
of trials, methodology assessment, and data extraction; corresponded with authors and pharmaceutical companies to identify other
relevant trials, verify methodology and data extraction, and request additional information; analysed and interpreted results of the meta-
analysis; and edited the final review.
Toby Lasserson (update 2006, 2010) assessed studies for inclusion or exclusion, extracted and entered data, revised results and discussion
sections, and solicited additional data from authors.
Christopher Cates edited the review, checked the methodology, and contributed to writing up the final review.
Felix Ram participated in the initial version of the review (2005): protocol design, identified and reviewed the full-text publication of
all citations of potential or potentially eligible RCTs, extracted the methodology and data, analysed and interpreted results of the meta-
analysis, and wrote the first draft of the review.
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Francine M Ducharme has received travel support for meeting attendance, research funds, fees for speaking and consulting fees
from Merck Frosst Inc (producer of montelukast), GlaxoSmithKline (producer of fluticasone, beclomethasone, salmeterol), Novartis
(producer of formoterol ) and Nycomed (producer of combination of mometasone and formoterol). No conflict was reported by Toby
Lasserson or Christopher Cates.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. In the protocol published in April 2001, we had planned to examine the impact of the inhaled glucocorticoids (subgroups 3)
and of baseline severity (subgroups 5) as sensitivity analyses but changed to subgroup analyses because this enhanced the clarity of
interpretation. The last two subgroup analyses (6 & 7), not initially considered in 2001, were added to the list subsequently as recent
data indicated that the number of inhaler devices to deliver LABA + ICS might be an important effect modifier (Nelson 2003), and a
peer reviewer suggested that differences might not be the same over 12 and 48 weeks.
2. Due to recent concerns over the association between LABAs and serious adverse events, we included a subgroup analysis of the
data by the number of inhaler devices.
3. Study assessment was amended to reflect changes in the recommended approach to risk of bias evaluation. In the original
protocol and first version of the review we assessed studies with the Jadad scale, and by grading concealment of allocation. For the
2010 update we have used a tool for assessing the degree of protection offered by the study design against systematic error. This is
outlined in the section: Assessment of risk of bias in included studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗therapeutic use]; Adrenergic beta-2 Receptor Agonists [∗therapeutic use]; Anti-Asthmatic Agents
[∗therapeutic use]; Asthma [∗drug therapy]; Chronic Disease; Drug Therapy, Combination; Leukotriene Antagonists [∗therapeutic
use]; Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Adult; Child; Humans
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